aspirin has been researched along with Nasal Catarrh in 205 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aspirin-induced chronic rhinosinusitis (CRS) is a severe progressive persistent disease, usually associated with nasal polyps (NPs)." | 9.30 | Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery. ( Barać, A; Gaćeša, D; Jožin, SM; Kovačević, SV; Perić, A; Perić, AV, 2019) |
| "Numerous open trials have demonstrated the beneficial clinical effects of aspirin desensitization (AD) in patients with aspirin-induced asthma (AIA)." | 9.19 | Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. ( Bochenek, G; Ćmiel, A; Gielicz, A; Niżankowska-Mogilnicka, E; Plutecka, H; Sanak, M; Stręk, P; Świerczyńska-Krępa, M; Szczeklik, A, 2014) |
| "Aspirin-exacerbated respiratory disease (AERD) is characterized by the clinical triad of chronic rhinosinusitis with nasal polyps, asthma, and an intolerance to medications that inhibit the cycloxgenase-1 enzyme." | 9.12 | The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, ( Baptist, AP; Borish, L; Bosso, JV; Buchheit, KM; Cahill, KN; Campo, P; Cho, SH; Jerschow, E; Keswani, A; Laidlaw, TM; Levy, JM; Nanda, A; Stevens, WW; White, AA, 2021) |
| "The aim of this study was to assess the efficacy of leucotrien- antagonists in aspirin-intolerant asthma (AIA)." | 9.10 | [The effectiveness of leukotriene antagonists in the treatment of aspirin-intolerant asthmatic patients]. ( Arvin-Berod, C; Paganin, F; Poubeau, P; Yvin, JL, 2003) |
| "Aspirin-induced asthma/rhinitis (AIAR) is characterized by the altered metabolism of leukotrienes and proinflammatory prostaglandins." | 9.10 | Nasal versus bronchial and nasal response to oral aspirin challenge: Clinical and biochemical differences between patients with aspirin-induced asthma/rhinitis. ( Gielicz, A; Nizankowska-Mogilnicka, E; Swierczynska, M; Szczeklik, A; Zarychta, J, 2003) |
| "We performed a double-blind, crossover, placebo-controlled study on the effect of fluticasone propionate (FP) treatment on chronic eosinophilic rhinosinusitis in 15 patients with aspirin-induced asthma (AIA)." | 9.08 | Intranasal fluticasone propionate for chronic eosinophilic rhinitis in patients with aspirin-induced asthma. ( Duplaga, M; Mastalerz, L; Milewski, M; Nizankowska, E; Szczeklik, A, 1997) |
| "Aspirin-Exacerbated Respiratory Disease (AERD) and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) are both characterized by the presence of chronic sinonasal inflammation and nasal polyps." | 8.93 | Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis. ( Schleimer, RP; Stevens, WW, 2016) |
| "Aspirin-exacerbated respiratory disease (AERD) is a clinical condition which results in adverse upper and lower respiratory symptoms, particularly rhinitis, conjunctivitis, bronchospasm, and/or laryngospasm, following exposure to cyclooxygenase-1 (COX-1) inhibiting drugs, namely aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)." | 8.91 | Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD). ( Dazy, KM; Simon, RA; Waldram, JD, 2015) |
| "Chronic rhinosinusitis patients with nasal polyps can be aspirin sensitive or aspirin tolerant." | 8.90 | Topical nasal lysine aspirin in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis with nasal polyposis. ( Parikh, A; Scadding, GK, 2014) |
| "Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma frequently coexist and are always present in patients with aspirin exacerbated respiratory disease (AERD)." | 8.90 | Prostaglandin E2 receptors in asthma and in chronic rhinosinusitis/nasal polyps with and without aspirin hypersensitivity. ( Machado-Carvalho, L; Picado, C; Roca-Ferrer, J, 2014) |
| "The presence of aspirin-exacerbated respiratory disease (AERD) in a patient with chronic rhinosinusitis with nasal polyps and asthma is associated with severe eosinophilic upper and lower airway disease." | 8.89 | Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease. ( Mullol, J; Picado, C, 2013) |
| "This review is set to revisit the pathogenesis of aspirin-exacerbated respiratory disease (AERD), the diagnostic method used, and finally the real impact of aspirin desensitization on chronic sinusitis with nasal polyposis (CRSwNP) in aspirin intolerant patients." | 8.87 | Role of aspirin desensitization in the management of chronic rhinosinusitis. ( Rizk, H, 2011) |
| "The purpose of this review is to highlight recent advances in gene-expression profiling of nasal polyps in patients with chronic rhinosinusitis and aspirin-sensitive asthma." | 8.85 | Gene-expression signatures of nasal polyps associated with chronic rhinosinusitis and aspirin-sensitive asthma. ( Metson, R; Platt, M; Stankovic, K, 2009) |
| "Aspirin-exacerbated respiratory disease (AERD) is a chronic inflammatory disease characterized by chronic rhinosinusitis, nasal polyposis, asthma, and airway reactivity to aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs)." | 8.84 | The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis. ( Williams, AN; Woessner, KM, 2008) |
| "To provide a diagnostic strategy for evaluating and treating patients with aspirin sensitivity, with additional consideration for issues specific to patients with coronary artery disease (CAD)." | 8.82 | Aspirin sensitivity: implications for patients with coronary artery disease. ( Gollapudi, RR; Simon, RA; Stevenson, DD; Teirstein, PS, 2004) |
| "Interesting findings relating to aspirin-induced asthma recently emerged." | 8.81 | Aspirin-induced rhinitis and asthma. ( Nizankowska, E; Sanak, M; Swierczynska, M; Szczeklik, A, 2001) |
| "Patients with asthma and nasal polyps have been warned to avoid aspirin because of a tendency to develop hypersensitivity reactions." | 8.77 | Desensitization to aspirin in aspirin-sensitive patients with rhino-sinusitis and asthma: a review. ( Knight, A, 1989) |
| " In our previous studies, we showed that the TNFA -308A allele is a genetic predisposition factor in a subgroup of aspirin-sensitive (ASA+) CRS patients suffering from nasal polyps (NP) in the Hungarian population." | 7.81 | A conserved linkage group on chromosome 6, the 8.1 ancestral haplotype, is a predisposing factor of chronic rhinosinusitis associated with nasal polyposis in aspirin-sensitive Hungarians. ( Bella, Z; Hirschberg, A; Kadocsa, E; Kemény, L; Kiricsi, Á; Polyánka, H; Révész, M; Szabó, K; Szabó, Z; Széll, M; Vóna, I, 2015) |
| "Chronic rhinosinusitis (CRS) with nasal polyposis (NP) may be associated with hypersensitivity to nonsteroidal anti-inflammatory drugs, representing a syndrome of aspirin-exacerbated respiratory disease (AERD)." | 7.78 | Incidence of aspirin hypersensitivity in patients with chronic rhinosinusitis and diagnostic value of urinary leukotriene E4. ( Celejewska-Wójcik, N; Cybulska, A; Hartwich, P; Hydzik-Sobocińska, K; Januszek, R; Mastalerz, L; Nieckarz, R; Oleś, K; Sanak, M; Stręk, P; Szaleniec, J; Wójcik, K, 2012) |
| "The present study inluded 22 patients presenting either with very severe or moderately severe aspirin triad 17 of whom suffered exacerbation of chronic polypous suppurative rhinosinusitis." | 7.77 | [The treatment of polypous suppurative rhinosinusitis in the patients presenting with the severe and moderate aspirin triad]. ( Riabova, MA; Shumilova, NA, 2011) |
| "Rhinosinusitis is highly associated with aspirin-intolerant asthma (AIA)." | 7.74 | Association between a TGFbeta1 promoter polymorphism and rhinosinusitis in aspirin-intolerant asthmatic patients. ( Holloway, JW; Kim, SH; Park, CS; Park, HS; Shin, HD, 2007) |
| "Cysteinyl leukotrienes play a disease-regulating role in rhinosinusitis and asthma, particularly aspirin-sensitive disease." | 7.73 | Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. ( Corrigan, C; Lee, T; Mallett, K; Parikh, A; Roberts, D; Scadding, G; Ying, S, 2005) |
| "Hypersensitivity to aspirin usually takes the form of a clinical syndrome combining chronic rhinitis, nasal polyposis and asthma attacks that are exacerbated by aspirin or other non steroidal anti-inflammatory drugs (NSAIDs)." | 7.73 | [New pathophysiological concepts on aspirin hypersensitivity (Widal syndrome); diagnostic and therapeutic consequences]. ( de Weck, A; Gamboa, P; Sanz, ML, 2005) |
| "To address the hypothesis that expression of 1 or more EP receptors on nasal mucosal inflammatory cells is deficient in patients with aspirin-sensitive compared with nonaspirin-sensitive polypoid rhinosinusitis." | 7.73 | Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells. ( Corrigan, CJ; Lee, TH; Meng, Q; Parikh, A; Scadding, G; Ying, S, 2006) |
| " Urinary leukotriene E4 concentration (LTE4), that reflects the whole body production of cysteinil-leukotrienes, is particularly increased in patients with aspirin-intolerant asthma (AIA)." | 7.73 | Aspirin induced asthma (AIA) with nasal polyps has the highest basal LTE4 excretion: a study vs AIA without polyps, mild topic asthma, and normal controls. ( Dal Negro, RW; Facchini, FM; Micheletto, C; Tognella, S; Visconti, M, 2006) |
| "There were significant differences in the expression of COX and LO enzymes between patients with nasal polyps and controls, irrespective of aspirin sensitivity." | 7.73 | Expression of cyclooxygenase and lipoxygenase enzymes in nasal polyps of aspirin-sensitive and aspirin-tolerant patients. ( Kingdom, TT; Owens, JM; Shroyer, KR, 2006) |
| "Aspirin-sensitive rhinitis is the manifestation of aspirin intolerance in the upper respiratory tract." | 7.72 | Aspirin-sensitive rhinitis-associated changes in upper airway innervation. ( Cryer, A; Dinh, QT; Fischer, A; Groneberg, DA; Heppt, W; Peiser, C; Welker, P; Witt, C; Zweng, M, 2003) |
| "The urinary leukotriene E4 (U-LTE4) concentration is significantly increased in patients with aspirin-intolerant asthma (AIA)." | 7.72 | Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. ( Akiyama, K; Higashi, A; Higashi, N; Ishii, T; Kawagishi, Y; Mita, H; Osame, M; Taniguchi, M, 2004) |
| "Nasal polyps were obtained from 16 aspirin-tolerant patients with asthma/rhinitis (ATAR) and 18 aspirin-intolerant patients with asthma/rhinitis (AIAR) undergoing nasal polypectomy." | 7.72 | Dynamics of COX-2 in nasal mucosa and nasal polyps from aspirin-tolerant and aspirin-intolerant patients with asthma. ( Alobid, I; Mullol, J; Picado, C; Pujols, L; Roca-Ferrer, J; Xaubet, A, 2004) |
| "Although many studies have assumed that the overproduction of cysteinyl- leukotrienes (cys-LTs) and an imbalance of arachidonic acid metabolism may be plausible causes for the pathogenesis of aspirin-intolerant asthma (AIA), there has been little experimental evidence to substantiate this notion in lower airways of patients with AIA." | 7.71 | A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma. ( Akiyama, K; Higashi, N; Mita, H; Osame, M; Taniguchi, M, 2002) |
| "Patients with aspirin-hypersensitive rhinosinusitis/asthma suffer from a severe form of hyperplastic rhinosinusitis with recurrent polyposis." | 7.71 | Decreased apoptosis and distinct profile of infiltrating cells in the nasal polyps of patients with aspirin hypersensitivity. ( Danilewicz, M; Grzegorczyk, J; Kornatowski, T; Kowalski, ML; Pawliczak, R; Wagrowska-Danilewicz, M, 2002) |
| "Nasal provocation tests with lysine-aspirin have recently been introduced for assessment of aspirin intolerant asthma." | 7.70 | Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry. ( Casadevall, J; Mullol, J; Picado, C; Ventura, PJ, 2000) |
| "The high prevalence of aspirin intolerance in asthmatics and patients with nasal polyps as well as reports of familial clustering suggest a genetic disposition of this disease." | 7.70 | [Family study of patients with aspirin intolerance and rhinosinusitis]. ( Langenbeck, U; May, A; Wagner, D; Weber, A, 2000) |
| "Inhalation and nasal aspirin challenge has been investigated in asthma patients with co-existing rhinitis." | 7.68 | Inhalation and nasal challenge in the diagnosis of aspirin-induced asthma. ( Davies, BH; Pawlowicz, A; Williams, WR, 1991) |
| "One hundred seven known aspirin (ASA)-sensitive patients with rhinosinusitis-asthma were studied from 1975 to 1988." | 7.68 | Long-term effects of aspirin desensitization--treatment for aspirin-sensitive rhinosinusitis-asthma. ( Mathison, DA; Simon, RA; Stevenson, DD; Sweet, JM, 1990) |
| "Aspirin-sensitive asthma is not well documented in children." | 7.66 | Aspirin-induced asthma in children. ( Collins-Williams, C; Tan, Y, 1982) |
| "Eleven patients with asthma and aspirin hypersensitivity have been challenged with eight non-steroidal anti-inflammatory drugs." | 7.65 | Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. ( Czerniawska-Mysik, G; Gryglewski, RJ; Szczeklik, A, 1975) |
| "Bronchial asthma is not a homogenous disease." | 6.41 | Diagnosis, prevention and treatment of aspirin-induced asthma and rhinitis. ( Bánska, K; Bochenek, G; Nizankowska, E; Szabó, Z; Szczeklik, A, 2002) |
| "Treatment of the nasal polyps has been shown to improve the patients' asthma." | 6.38 | Nasal polyps, bronchial asthma and aspirin sensitivity. ( Hawke, M; Jeney, E; Probst, L; Stoney, P, 1992) |
| "Aspirin sensitivity has a highly significant association with AFRS." | 5.48 | Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study. ( Ahmed, S; Almeyda, R; Anari, S; Carrie, S; Cathcart, R; Clark, A; Coombes, E; Erskine, S; Farboud, A; Hobson, J; Hopkins, C; Jervis, P; Kara, N; Khalil, H; Kumar, N; Mansell, N; Panesaar, J; Philpott, C; Philpott, CM; Prinsley, P; Ray, J; Robertson, A; Salam, M; Sunkaraneni, S; Sunkaraneni, V; Wilson, A; Woods, J, 2018) |
| "Aspirin-exacerbated respiratory disease (AERD) is characterized by abnormal arachidonic acid metabolism leading to chronic rhinosinusitis with nasal polyposis (CRSwNP), asthma, and upper and/or lower respiratory symptoms after ingestion of cyclooxygenase-1 inhibiting nonsteroidal antiinflammatory drugs." | 5.41 | Aspirin-Exacerbated Respiratory Disease and the Unified Airway: A Contemporary Review. ( Choby, G; Divekar, RD; Hagan, JB; O'Brien, EK; Pinheiro-Neto, CD; Stokken, JK; Walters, BK; Willson, TJ, 2023) |
| "Aspirin-exacerbated respiratory disease (AERD) is a chronic respiratory condition characterized by severe chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic asthma, and respiratory reactions to cyclooxygenase inhibitors." | 5.41 | Aspirin-exacerbated respiratory disease: Updates in the era of biologics. ( Buchheit, KM; Mullur, J, 2023) |
| "These post hoc analyses of pooled data from 2 BREATH phase 3 clinical trials, studies 1 and 2 (NCT01287039 and NCT01285323), examined asthma-related outcomes in patients with comorbid, self-reported CRSwNP with and without aspirin sensitivity." | 5.30 | Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps. ( Bardin, P; Bateman, ED; Garin, M; Germinaro, M; Hoyte, FCL; Katial, RK; Korn, S; McDonald, M; Weinstein, SF, 2019) |
| "Aspirin-induced chronic rhinosinusitis (CRS) is a severe progressive persistent disease, usually associated with nasal polyps (NPs)." | 5.30 | Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery. ( Barać, A; Gaćeša, D; Jožin, SM; Kovačević, SV; Perić, A; Perić, AV, 2019) |
| "Tissue eosinophilia is regulated by chemical attractants and activating substances of various origins and plays a major part in the chronic inflammatory state." | 5.28 | Nonallergic rhinitis with eosinophilia syndrome a precursor of the triad: nasal polyposis, intrinsic asthma, and intolerance to aspirin. ( Guyot, JL; Hsieh, V; Maria, Y; Moneret-Vautrin, DA; Mouton, C; Wayoff, M, 1990) |
| "Aspirin exacerbated respiratory disease (AERD) is comprised of aspirin/acetylsalicylic acid (ASA) sensitivity, bronchial asthma, and nasal polyposis." | 5.20 | Treatment of aspirin exacerbated respiratory disease with a low salicylate diet: a pilot crossover study. ( Au, M; Gupta, MK; Hoffbauer, S; Nayan, S; Sommer, DD; Sowerby, LJ, 2015) |
| "Numerous open trials have demonstrated the beneficial clinical effects of aspirin desensitization (AD) in patients with aspirin-induced asthma (AIA)." | 5.19 | Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. ( Bochenek, G; Ćmiel, A; Gielicz, A; Niżankowska-Mogilnicka, E; Plutecka, H; Sanak, M; Stręk, P; Świerczyńska-Krępa, M; Szczeklik, A, 2014) |
| "To determine acute analgesia by acetylsalicylic acid (ASA) when combined with pseudoephedrine (PSE) in patients with upper respiratory tract infection (URTI), we used the sore throat pain model to measure single-dose effects of ASA 500 mg/PSE 30 mg, ASA 1000 mg/PSE 60 mg, and acetaminophen (APAP) 1000 mg/PSE 60 mg (serving as a positive control)." | 5.14 | Demonstration of the analgesic efficacy and dose-response of acetylsalicylic acid with pseudoephedrine. ( Becka, M; Bey, M; Gagney, D; Sanner, KM; Schachtel, BP; Schachtel, EJ; Voelker, M, 2010) |
| "Aspirin-exacerbated respiratory disease (AERD) is characterized by the clinical triad of chronic rhinosinusitis with nasal polyps, asthma, and an intolerance to medications that inhibit the cycloxgenase-1 enzyme." | 5.12 | The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, ( Baptist, AP; Borish, L; Bosso, JV; Buchheit, KM; Cahill, KN; Campo, P; Cho, SH; Jerschow, E; Keswani, A; Laidlaw, TM; Levy, JM; Nanda, A; Stevens, WW; White, AA, 2021) |
| "The aim of this study was to assess the efficacy of leucotrien- antagonists in aspirin-intolerant asthma (AIA)." | 5.10 | [The effectiveness of leukotriene antagonists in the treatment of aspirin-intolerant asthmatic patients]. ( Arvin-Berod, C; Paganin, F; Poubeau, P; Yvin, JL, 2003) |
| "Aspirin-induced asthma/rhinitis (AIAR) is characterized by the altered metabolism of leukotrienes and proinflammatory prostaglandins." | 5.10 | Nasal versus bronchial and nasal response to oral aspirin challenge: Clinical and biochemical differences between patients with aspirin-induced asthma/rhinitis. ( Gielicz, A; Nizankowska-Mogilnicka, E; Swierczynska, M; Szczeklik, A; Zarychta, J, 2003) |
| "We performed a double-blind, crossover, placebo-controlled study on the effect of fluticasone propionate (FP) treatment on chronic eosinophilic rhinosinusitis in 15 patients with aspirin-induced asthma (AIA)." | 5.08 | Intranasal fluticasone propionate for chronic eosinophilic rhinitis in patients with aspirin-induced asthma. ( Duplaga, M; Mastalerz, L; Milewski, M; Nizankowska, E; Szczeklik, A, 1997) |
| "Aspirin-exacerbated respiratory disease (AERD) represents an aggressive form of chronic rhinosinusitis with nasal polyposis that is notoriously challenging to treat." | 5.05 | Aspirin desensitization therapy in aspirin-exacerbated respiratory disease: a systematic review. ( Chin, CJ; Larivée, N, 2020) |
| "Aspirin-exacerbated respiratory disease is a chronic and treatment-resistant disease, characterized by the presence of eosinophilic rhinosinusitis, nasal polyposis, bronchial asthma, and nonsteroidal anti-inflammatory drugs hypersensitivity." | 4.98 | Aspirin exacerbated respiratory disease: Current topics and trends. ( Guaní-Guerra, E; Moreno-Paz, FJ; Rodríguez-Jiménez, JC; Terán, LM, 2018) |
| "Aspirin-exacerbated respiratory disease (AERD) refers to the combination of asthma, chronic rhinosinusitis with nasal polyposis, and acute upper and lower respiratory tract reactions to the ingestion of aspirin (acetylsalicylic acid, ASA) and other cyclooxygenase-1 inhibiting non-steroidal anti-inflammatory drugs." | 4.95 | Aspirin-exacerbated respiratory disease and current treatment modalities. ( Cingi, C; Kar, M; Muluk, NB; Sakalar, EG, 2017) |
| "Aspirin-exacerbated respiratory disease (AERD) represents a severe form of chronic rhinosinusitis (CRS) characterized by nasal polyposis, bronchial asthma, and aspirin intolerance." | 4.93 | The Role of Surgery in Management of Samter's Triad: A Systematic Review. ( Adelman, J; Krouse, JH; McLean, C; Shaigany, K, 2016) |
| "Aspirin-Exacerbated Respiratory Disease (AERD) and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) are both characterized by the presence of chronic sinonasal inflammation and nasal polyps." | 4.93 | Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis. ( Schleimer, RP; Stevens, WW, 2016) |
| "Aspirin-exacerbated respiratory disease is defined by the clinical tetrad of aspirin sensitivity, nasal polyps, asthma, and chronic rhinosinusitis." | 4.93 | Current complications and treatment of aspirin-exacerbated respiratory disease. ( Cook, KA; Stevenson, DD, 2016) |
| "Aspirin-exacerbated respiratory disease (AERD) is a clinical condition which results in adverse upper and lower respiratory symptoms, particularly rhinitis, conjunctivitis, bronchospasm, and/or laryngospasm, following exposure to cyclooxygenase-1 (COX-1) inhibiting drugs, namely aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)." | 4.91 | Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD). ( Dazy, KM; Simon, RA; Waldram, JD, 2015) |
| "Aspirin-exacerbated respiratory disease is a clinical entity comprising chronic rhinosinusitis with nasal polyposis, asthma and intolerance to COX-1 inhibiting drugs." | 4.91 | Aspirin-exacerbated respiratory disease: characteristics and management strategies. ( Dazy, KM; Simon, RA; Waldram, JD, 2015) |
| "Hypersensitivity to acetylsalicylic acid (ASA) is characterized by the co-occurrence of symptoms so-called aspirin triad, which include bronchial asthma, chronic rhinitis and sinusitis and the nasal mucosa polyps." | 4.91 | [Hypersensitivity to acetylsalicylic acid]. ( Skrętkowicz, J; Wojtczak, A, 2015) |
| " Several clinical phenotypes often leading to uncontrolled disease, including adult nasal polyposis, aspirin-exacerbated respiratory disease, and allergic fungal rhinosinusitis, are characterized by a common endotype: a TH2 bias is associated with a higher likelihood of comorbid asthma and recurrence after surgical treatment." | 4.91 | Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis. ( Bachert, C; Gevaert, P; Zhang, L, 2015) |
| "Chronic rhinosinusitis patients with nasal polyps can be aspirin sensitive or aspirin tolerant." | 4.90 | Topical nasal lysine aspirin in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis with nasal polyposis. ( Parikh, A; Scadding, GK, 2014) |
| "Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma frequently coexist and are always present in patients with aspirin exacerbated respiratory disease (AERD)." | 4.90 | Prostaglandin E2 receptors in asthma and in chronic rhinosinusitis/nasal polyps with and without aspirin hypersensitivity. ( Machado-Carvalho, L; Picado, C; Roca-Ferrer, J, 2014) |
| "The presence of aspirin-exacerbated respiratory disease (AERD) in a patient with chronic rhinosinusitis with nasal polyps and asthma is associated with severe eosinophilic upper and lower airway disease." | 4.89 | Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease. ( Mullol, J; Picado, C, 2013) |
| "This review is set to revisit the pathogenesis of aspirin-exacerbated respiratory disease (AERD), the diagnostic method used, and finally the real impact of aspirin desensitization on chronic sinusitis with nasal polyposis (CRSwNP) in aspirin intolerant patients." | 4.87 | Role of aspirin desensitization in the management of chronic rhinosinusitis. ( Rizk, H, 2011) |
| "The purpose of this review is to highlight recent advances in gene-expression profiling of nasal polyps in patients with chronic rhinosinusitis and aspirin-sensitive asthma." | 4.85 | Gene-expression signatures of nasal polyps associated with chronic rhinosinusitis and aspirin-sensitive asthma. ( Metson, R; Platt, M; Stankovic, K, 2009) |
| "Aspirin-exacerbated respiratory disease (AERD) is a chronic inflammatory disease characterized by chronic rhinosinusitis, nasal polyposis, asthma, and airway reactivity to aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs)." | 4.84 | The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis. ( Williams, AN; Woessner, KM, 2008) |
| "In up to 10% of patients with bronchial asthma, aspirin and other nonsteroidal antiinflammatory drugs precipitate asthmatic attacks." | 4.82 | Aspirin intolerance and the cyclooxygenase-leukotriene pathways. ( Kiełbasa, B; Nizankowska-Mogilnicka, E; Sanak, M; Szczeklik, A, 2004) |
| "To provide a diagnostic strategy for evaluating and treating patients with aspirin sensitivity, with additional consideration for issues specific to patients with coronary artery disease (CAD)." | 4.82 | Aspirin sensitivity: implications for patients with coronary artery disease. ( Gollapudi, RR; Simon, RA; Stevenson, DD; Teirstein, PS, 2004) |
| " However, recently there has been some progress in elucidating the etiology of nasal polyposis, especially regarding tissue eosinophilia as well as the role of aspirin intolerance and eicosanoid mediators." | 4.82 | Current concepts in therapy of chronic rhinosinusitis and nasal polyposis. ( Gosepath, J; Mann, WJ, 2005) |
| "Chronic rhinosinusitis with nasal polyposis usually develops in aspirin-sensitive patients with asthma Arachidonic acid metabolism appears to be abnormal in the nasal polyps of aspirin-sensitive patients with asthma." | 4.81 | Aspirin intolerance and nasal polyposis. ( Picado, C, 2002) |
| "Relevant articles in the medical literature were derived from searching the MEDLINE database with key terms aspirin-sensitive asthma, cyclo-oxygenase enzymes 1 and 2." | 4.81 | Sensitivity to nonsteroidal anti-inflammatory drugs. ( Namazy, JA; Simon, RA, 2002) |
| "Interesting findings relating to aspirin-induced asthma recently emerged." | 4.81 | Aspirin-induced rhinitis and asthma. ( Nizankowska, E; Sanak, M; Swierczynska, M; Szczeklik, A, 2001) |
| "Patients with asthma and nasal polyps have been warned to avoid aspirin because of a tendency to develop hypersensitivity reactions." | 4.77 | Desensitization to aspirin in aspirin-sensitive patients with rhino-sinusitis and asthma: a review. ( Knight, A, 1989) |
| "Aspirin intolerance manifests itself as an acute urticaria-angioedema, bronchospasm, severe rhinitis, or shock occurring within three hours of aspirin ingestion." | 4.76 | Aspirin and allergic diseases: a review. ( Settipane, GA, 1983) |
| "Aspirin desensitization (AD) is effective in relieving asthma and sinonasal outcomes in patients with non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD)." | 4.31 | Aspirin desensitization following endoscopic sinus surgery is effective in patients with nonsteroidal antiinflammatory drug exacerbated respiratory disease. ( Anadolu, Y; Atmiş, EÖ; Aydin, Ö; Çelik, GE; Yorulmaz, İ, 2023) |
| "These evidence-based guidelines support patients, clinicians, and other stakeholders in decisions about the use of intranasal corticosteroids (INCS), biologics, and aspirin therapy after desensitization (ATAD) for the management of chronic rhinosinusitis with nasal polyposis (CRSwNP)." | 4.31 | The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. ( Bernstein, JA; Bognanni, A; Chu, DK; Ellis, AK; Golden, DBK; Greenhawt, M; Horner, CC; Ledford, DK; Lieberman, J; Luong, AU; Orlandi, RR; Oykhman, P; Peters, AT; Rank, MA; Samant, SA; Shaker, MS; Soler, ZM; Stevens, WW; Stukus, DR; Wang, J, 2023) |
| "A total of 30 patients with AERD, 30 chronic rhinosinusitis (CRS) with NP patients without aspirin sensitivity (CRSwNP), and 30 control subjects without inflammation of the nasal mucosa (C), selected for surgical treatment entered the study." | 4.31 | Inflammatory mediators in nasal secretions of patients with nasal polyposis with and without aspirin sensitivity. ( Cvetković, G; Gaćeša, D; Perić, A; Vojvodić, D, 2023) |
| "Aspirin-exacerbated respiratory disease (AERD) is a unique and often clinically severe disease affecting a subgroup of adults with asthma and chronic rhinosinusitis with nasal polyposis." | 4.31 | Mechanistic and clinical updates in AERD: 2021-2022. ( Cahill, KN; Stevens, WW, 2023) |
| " Quantitative and descriptive analyses of age, gender, nationality, presence of polyps, aspirin sensitivity, presence of urticaria, asthma, and allergies were performed." | 4.31 | Demographic and clinical profile of patients with chronic rhinosinusitis in Saudi Arabia. ( Alanazy, F; Alfallaj, R; Almousa, H; Aloulah, M; Alrasheed, A; Alromaih, S; Alroqi, AS; Alsaleh, S; Dousary, SA; Ismail, D; Mahjoub, S; Obaid, SB, 2023) |
| "Aspirin-exacerbated respiratory disease (AERD) consists of chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, and hypersensitivity to aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)." | 4.31 | Association Between Aspirin-Exacerbated Respiratory Disease and Atherosclerotic Cardiovascular Disease: A Retrospective Review of US Claims Data. ( Adame, MJ; Kuo, YF; Raji, M; Shan, Y; Tripple, JW; Zhang, Y, 2023) |
| "Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) asthma is characterized by chronic rhinosinusitis and intolerance of aspirin and other COX1 inhibitors." | 4.02 | Heterogeneity of lower airway inflammation in patients with NSAID-exacerbated respiratory disease. ( Bochenek, G; Gielicz, A; Jakiela, B; Plutecka, H; Przybyszowski, M; Rebane, A; Sladek, K; Soja, J, 2021) |
| "Aspirin-exacerbated respiratory disease (AERD) is a severe form of chronic rhinosinusitis with nasal polyps (CRSwNP) accompanied by asthma and an aspirin intolerance." | 3.96 | The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease (AERD) undergoing aspirin desensitization: preliminary data. ( Eder, K; Gellrich, D; Gröger, M; Högerle, C; Pfrogner, E; San Nicoló, M, 2020) |
| "Aspirin-exacerbated respiratory disease (AERD) represents a severe endotype of chronic rhinosinusitis with nasal polyposis." | 3.96 | Surgical outcomes in aspirin-exacerbated respiratory disease without aspirin desensitization. ( Cottrell, J; Grose, E; Lee, DJ; Lee, JK; Lee, JM; Sykes, J; Yip, J, 2020) |
| "Background Aspirin-exacerbated respiratory disease (AERD), also known as Samter's triad or aspirin (ASA)-intolerant asthma, affects 7% of asthmatics and has a higher prevalence in those with chronic rhinosinusitis and concomitant nasal polyposis." | 3.88 | Long-term Clinical Outcomes of Aspirin Desensitization With Continuous Daily Aspirin Therapy in Aspirin-exacerbated Respiratory Disease. ( Waldram, JD; Walters, KM; White, AA; Woessner, KM, 2018) |
| "Oral aspirin challenge (OAC) reveals aspirin-exacerbated respiratory disease (AERD) in approximately 50% of unselected patients with chronic rhinosinusitis with nasal polyposis (CRSwNP)." | 3.85 | Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study. ( Gudziol, V; Hummel, T; Koschel, D; Michel, M; Sonnefeld, C, 2017) |
| " In our previous studies, we showed that the TNFA -308A allele is a genetic predisposition factor in a subgroup of aspirin-sensitive (ASA+) CRS patients suffering from nasal polyps (NP) in the Hungarian population." | 3.81 | A conserved linkage group on chromosome 6, the 8.1 ancestral haplotype, is a predisposing factor of chronic rhinosinusitis associated with nasal polyposis in aspirin-sensitive Hungarians. ( Bella, Z; Hirschberg, A; Kadocsa, E; Kemény, L; Kiricsi, Á; Polyánka, H; Révész, M; Szabó, K; Szabó, Z; Széll, M; Vóna, I, 2015) |
| "To demonstrate that quality-of-life outcomes after endoscopic sinus surgery are not compromised in patients with Samter's triad (asthma, nasal polyps, aspirin sensitivity) when compared to patients with eosinophilic chronic rhinosinusitis with nasal polyposis (eCRSwP) who are not aspirin sensitive." | 3.80 | Aspirin sensitivity does not compromise quality-of-life outcomes in patients with Samter's triad. ( Comer, BT; Jang, DW; Kountakis, SE; Lachanas, VA, 2014) |
| " The impact of surgery and factors such as the presence of polyps, asthma, and aspirin sensitivity on the bacterial state are poorly understood." | 3.79 | The bacteriology of chronic rhinosinusitis and the pre-eminence of Staphylococcus aureus in revision patients. ( Bassiouni, A; Cleland, EJ; Wormald, PJ, 2013) |
| "SPINK5 single-nucleotide polymorphisms (SNPs) and SPINK5 expression levels were correlated with CRS without (CRSsNP) and with nasal polyps (CRSwNP), aspirin intolerance, asthma, and allergies." | 3.78 | Low SPINK5 expression in chronic rhinosinusitis. ( Brieger, J; Fruth, K; Goebel, G; Gosepath, J; Koutsimpelas, D; Mann, WJ; Schmidtmann, I, 2012) |
| "Chronic rhinosinusitis (CRS) with nasal polyposis (NP) may be associated with hypersensitivity to nonsteroidal anti-inflammatory drugs, representing a syndrome of aspirin-exacerbated respiratory disease (AERD)." | 3.78 | Incidence of aspirin hypersensitivity in patients with chronic rhinosinusitis and diagnostic value of urinary leukotriene E4. ( Celejewska-Wójcik, N; Cybulska, A; Hartwich, P; Hydzik-Sobocińska, K; Januszek, R; Mastalerz, L; Nieckarz, R; Oleś, K; Sanak, M; Stręk, P; Szaleniec, J; Wójcik, K, 2012) |
| "The present study inluded 22 patients presenting either with very severe or moderately severe aspirin triad 17 of whom suffered exacerbation of chronic polypous suppurative rhinosinusitis." | 3.77 | [The treatment of polypous suppurative rhinosinusitis in the patients presenting with the severe and moderate aspirin triad]. ( Riabova, MA; Shumilova, NA, 2011) |
| "It was the aim of this study to investigate the prevalence of otologic manifestations in a cohort of Samter's syndrome patients (nasal polyps with chronic rhinosinusitis, aspirin intolerance and asthma)." | 3.75 | Otologic manifestations in Samter's syndrome. ( Caversaccio, M; Häusler, R; Helbling, A, 2009) |
| " In these cases, CRS tends to be associated with bronchial asthma (BA), especially, aspirin-intolerant asthma (AIA)." | 3.74 | Correlation between the prostaglandin D(2)/E(2) ratio in nasal polyps and the recalcitrant pathophysiology of chronic rhinosinusitis associated with bronchial asthma. ( Haruna, S; Moriyama, H; Otori, N; Yoshikawa, M; Yoshimura, T, 2008) |
| "Rhinosinusitis is highly associated with aspirin-intolerant asthma (AIA)." | 3.74 | Association between a TGFbeta1 promoter polymorphism and rhinosinusitis in aspirin-intolerant asthmatic patients. ( Holloway, JW; Kim, SH; Park, CS; Park, HS; Shin, HD, 2007) |
| "Aspirin desensitization is indicated for patients who have aspirin-exacerbated respiratory disease and whose asthma and/or rhinosinusitis is suboptimally controlled with inhaled corticosteroids and leukotriene-modifying drugs." | 3.74 | Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. ( Bernstein, JA; Castells, MC; Gawchik, SM; Lee, TH; Macy, E; Settipane, RA; Simon, RA; Wald, J; Woessner, KM, 2007) |
| "We conducted a retrospective study to determine the prevalence of Samter's triad (nasal polyps, asthma, and aspirin sensitivity) in 208 consecutively presenting patients who had undergone functional endoscopic sinus surgery (FESS) for chronic rhinosinusitis from September 2001 through August 2003." | 3.74 | The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery. ( Kim, JE; Kountakis, SE, 2007) |
| " Underlying conditions such as immune deficiency, Wegener's granulomatosis, Churg-Strauss syndrome, aspirin hypersensitivity and allergic fungal sinusitis may present as rhinosinusitis." | 3.74 | BSACI guidelines for the management of rhinosinusitis and nasal polyposis. ( Dixon, TA; Drake-Lee, AB; Durham, SR; Huber, PA; Jones, NS; Mirakian, R; Nasser, SM; Ryan, D; Scadding, GK, 2008) |
| "Cysteinyl leukotrienes play a disease-regulating role in rhinosinusitis and asthma, particularly aspirin-sensitive disease." | 3.73 | Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. ( Corrigan, C; Lee, T; Mallett, K; Parikh, A; Roberts, D; Scadding, G; Ying, S, 2005) |
| "We have previously demonstrated that aspirin triggers specific generation of 15-hydroxyeicosateraenoic acid (15-HETE) from nasal polyp epithelial cells and peripheral blood leukocytes (PBL) from aspirin-sensitive (AS) but not aspirin-tolerant (AT) patients with asthma/rhinosinusitis." | 3.73 | Aspirin-triggered 15-HETE generation in peripheral blood leukocytes is a specific and sensitive Aspirin-Sensitive Patients Identification Test (ASPITest). ( Bienkiewicz, B; Cieslak, M; Dubuske, L; Grzegorczyk, J; Jedrzejczak, M; Kowalski, ML; Pawliczak, R; Ptasinska, A, 2005) |
| "Hypersensitivity to aspirin usually takes the form of a clinical syndrome combining chronic rhinitis, nasal polyposis and asthma attacks that are exacerbated by aspirin or other non steroidal anti-inflammatory drugs (NSAIDs)." | 3.73 | [New pathophysiological concepts on aspirin hypersensitivity (Widal syndrome); diagnostic and therapeutic consequences]. ( de Weck, A; Gamboa, P; Sanz, ML, 2005) |
| "To address the hypothesis that expression of 1 or more EP receptors on nasal mucosal inflammatory cells is deficient in patients with aspirin-sensitive compared with nonaspirin-sensitive polypoid rhinosinusitis." | 3.73 | Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells. ( Corrigan, CJ; Lee, TH; Meng, Q; Parikh, A; Scadding, G; Ying, S, 2006) |
| " Urinary leukotriene E4 concentration (LTE4), that reflects the whole body production of cysteinil-leukotrienes, is particularly increased in patients with aspirin-intolerant asthma (AIA)." | 3.73 | Aspirin induced asthma (AIA) with nasal polyps has the highest basal LTE4 excretion: a study vs AIA without polyps, mild topic asthma, and normal controls. ( Dal Negro, RW; Facchini, FM; Micheletto, C; Tognella, S; Visconti, M, 2006) |
| "There were significant differences in the expression of COX and LO enzymes between patients with nasal polyps and controls, irrespective of aspirin sensitivity." | 3.73 | Expression of cyclooxygenase and lipoxygenase enzymes in nasal polyps of aspirin-sensitive and aspirin-tolerant patients. ( Kingdom, TT; Owens, JM; Shroyer, KR, 2006) |
| "Aspirin-sensitive rhinitis is the manifestation of aspirin intolerance in the upper respiratory tract." | 3.72 | Aspirin-sensitive rhinitis-associated changes in upper airway innervation. ( Cryer, A; Dinh, QT; Fischer, A; Groneberg, DA; Heppt, W; Peiser, C; Welker, P; Witt, C; Zweng, M, 2003) |
| "The urinary leukotriene E4 (U-LTE4) concentration is significantly increased in patients with aspirin-intolerant asthma (AIA)." | 3.72 | Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. ( Akiyama, K; Higashi, A; Higashi, N; Ishii, T; Kawagishi, Y; Mita, H; Osame, M; Taniguchi, M, 2004) |
| "Nasal polyps were obtained from 16 aspirin-tolerant patients with asthma/rhinitis (ATAR) and 18 aspirin-intolerant patients with asthma/rhinitis (AIAR) undergoing nasal polypectomy." | 3.72 | Dynamics of COX-2 in nasal mucosa and nasal polyps from aspirin-tolerant and aspirin-intolerant patients with asthma. ( Alobid, I; Mullol, J; Picado, C; Pujols, L; Roca-Ferrer, J; Xaubet, A, 2004) |
| "Although many studies have assumed that the overproduction of cysteinyl- leukotrienes (cys-LTs) and an imbalance of arachidonic acid metabolism may be plausible causes for the pathogenesis of aspirin-intolerant asthma (AIA), there has been little experimental evidence to substantiate this notion in lower airways of patients with AIA." | 3.71 | A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma. ( Akiyama, K; Higashi, N; Mita, H; Osame, M; Taniguchi, M, 2002) |
| "Aspirin-exacerbated respiratory disease (AERD) is a clinical syndrome characterized by chronic rhinitis, nasal polyps, asthma, and precipitation of asthma and rhinitis attacks after ingestion of aspirin (ASA) and most nonsteroidal anti-inflammatory drugs (NSAIDs)." | 3.71 | The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. ( Berges-Gimeno, MP; Simon, RA; Stevenson, DD, 2002) |
| "Patients with aspirin-sensitive rhinosinusitis, which is frequently associated with intrinsic bronchial asthma, can be desensitized by long-term treatment with oral aspirin." | 3.71 | Individual monitoring of aspirin desensitization. ( Amedee, RG; Gosepath, J; Mann, WJ; Schaefer, D, 2001) |
| "Patients with aspirin-hypersensitive rhinosinusitis/asthma suffer from a severe form of hyperplastic rhinosinusitis with recurrent polyposis." | 3.71 | Decreased apoptosis and distinct profile of infiltrating cells in the nasal polyps of patients with aspirin hypersensitivity. ( Danilewicz, M; Grzegorczyk, J; Kornatowski, T; Kowalski, ML; Pawliczak, R; Wagrowska-Danilewicz, M, 2002) |
| "Between 8-20 percent of adult asthmatics experience bronchospasm following ingestion of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs)." | 3.70 | NSAID-induced bronchospasm--a common and serious problem. A report from MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority. ( Sturtevant, J, 1999) |
| "Nasal provocation tests with lysine-aspirin have recently been introduced for assessment of aspirin intolerant asthma." | 3.70 | Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry. ( Casadevall, J; Mullol, J; Picado, C; Ventura, PJ, 2000) |
| "The high prevalence of aspirin intolerance in asthmatics and patients with nasal polyps as well as reports of familial clustering suggest a genetic disposition of this disease." | 3.70 | [Family study of patients with aspirin intolerance and rhinosinusitis]. ( Langenbeck, U; May, A; Wagner, D; Weber, A, 2000) |
| " ASA challenges were performed in 17 ASA-sensitive patients with asthma and rhinosinusitis, and tryptase and histamine levels were measured in their venous blood samples." | 3.68 | Tryptase and histamine release during aspirin-induced respiratory reactions. ( Bosso, JV; Schwartz, LB; Stevenson, DD, 1991) |
| "Inhalation and nasal aspirin challenge has been investigated in asthma patients with co-existing rhinitis." | 3.68 | Inhalation and nasal challenge in the diagnosis of aspirin-induced asthma. ( Davies, BH; Pawlowicz, A; Williams, WR, 1991) |
| "One hundred seven known aspirin (ASA)-sensitive patients with rhinosinusitis-asthma were studied from 1975 to 1988." | 3.68 | Long-term effects of aspirin desensitization--treatment for aspirin-sensitive rhinosinusitis-asthma. ( Mathison, DA; Simon, RA; Stevenson, DD; Sweet, JM, 1990) |
| "Aspirin-sensitive asthma is not well documented in children." | 3.66 | Aspirin-induced asthma in children. ( Collins-Williams, C; Tan, Y, 1982) |
| "Eleven patients with asthma and aspirin hypersensitivity have been challenged with eight non-steroidal anti-inflammatory drugs." | 3.65 | Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. ( Czerniawska-Mysik, G; Gryglewski, RJ; Szczeklik, A, 1975) |
| "The aspirin intolerance syndrome is characterized by rhinitis and/or sinusitis, nasal polyposis and asthma, with or without a history of adverse reactions, following aspirin ingestion." | 3.65 | Intolerance to aspirin. ( Casterline, CL, 1975) |
| "Rhinosinusitis is among the most common infectious complications of humoral immunodeficiency, which is not uncommon in patients with refractory CRS." | 2.46 | Rhinosinusitis and comorbidities. ( Brooks, EG; Ryan, MW, 2010) |
| "Chronic rhinosinusitis is often associated with bronchial asthma." | 2.45 | [Chronic rhinosinusitis in morbus widal: clinical aspects and therapeutic options]. ( Jung, H, 2009) |
| "Rhinosinusitis is among the most common infectious complications of humoral immunodeficiency, and humoral immunodeficiency is not uncommon in patients with refractory chronic rhinosinusitis." | 2.44 | Diseases associated with chronic rhinosinusitis: what is the significance? ( Ryan, MW, 2008) |
| "Eosinophilia is frequently, but not exclusively, caused by immunoglobulin (Ig)E-mediated hypersensitivity and is dominated by the associated cytokine milieu of Th2 inflammation." | 2.43 | Differential diagnosis of eosinophilic chronic rhinosinusitis. ( Ferguson, BJ; Sok, JC, 2006) |
| "Bronchial asthma is not a homogenous disease." | 2.41 | Diagnosis, prevention and treatment of aspirin-induced asthma and rhinitis. ( Bánska, K; Bochenek, G; Nizankowska, E; Szabó, Z; Szczeklik, A, 2002) |
| "Nasal polyps are histologically characterized by massive edema and accumulation of eosinophils." | 2.39 | Eosinophils in the pathophysiology of nasal polyposis. ( Jankowski, R, 1996) |
| "Treatment of the nasal polyps has been shown to improve the patients' asthma." | 2.38 | Nasal polyps, bronchial asthma and aspirin sensitivity. ( Hawke, M; Jeney, E; Probst, L; Stoney, P, 1992) |
| " Long-term administration of acetylsalicylic acid (ASA) after desensitization has been used to mitigate these sequelae, but the optimal dose and balancing symptom relief and side effects remain unsettled." | 1.56 | Symptom Control of Patients With Chronic Rhinosinusitis With Nasal Polyps Under Maintenance Therapy With Daily Acetylsalicylic Acid. ( Appel, H; Greve, J; Hahn, J; Hoffmann, TK; Lindemann, J; Petereit, F; Scheithauer, MO; Sommer, F; Veit, JA, 2020) |
| "Aspirin sensitivity has a highly significant association with AFRS." | 1.48 | Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study. ( Ahmed, S; Almeyda, R; Anari, S; Carrie, S; Cathcart, R; Clark, A; Coombes, E; Erskine, S; Farboud, A; Hobson, J; Hopkins, C; Jervis, P; Kara, N; Khalil, H; Kumar, N; Mansell, N; Panesaar, J; Philpott, C; Philpott, CM; Prinsley, P; Ray, J; Robertson, A; Salam, M; Sunkaraneni, S; Sunkaraneni, V; Wilson, A; Woods, J, 2018) |
| "Prednisone was the most common OCS prescribed." | 1.46 | Oral corticosteroid prescribing habits for rhinosinusitis: The American Rhinologic Society membership. ( Ernst, HM; Rotenberg, BW; Rudmik, L; Scott, JR; Sowerby, LJ, 2017) |
| "Sinusitis is both prevalent and costly, affecting more than 14% of the population and costing more than $3." | 1.30 | Medical management of sinusitis. ( Kaliner, M, 1998) |
| "Tissue eosinophilia is regulated by chemical attractants and activating substances of various origins and plays a major part in the chronic inflammatory state." | 1.28 | Nonallergic rhinitis with eosinophilia syndrome a precursor of the triad: nasal polyposis, intrinsic asthma, and intolerance to aspirin. ( Guyot, JL; Hsieh, V; Maria, Y; Moneret-Vautrin, DA; Mouton, C; Wayoff, M, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 34 (16.59) | 18.7374 |
| 1990's | 15 (7.32) | 18.2507 |
| 2000's | 60 (29.27) | 29.6817 |
| 2010's | 56 (27.32) | 24.3611 |
| 2020's | 40 (19.51) | 2.80 |
| Authors | Studies |
|---|---|
| Wangberg, H | 2 |
| Spierling Bagsic, SR | 2 |
| Osuna, L | 1 |
| White, AA | 5 |
| Bertlich, M | 1 |
| Ihler, F | 1 |
| Bertlich, I | 1 |
| Weiss, BG | 1 |
| Gröger, M | 2 |
| Haubner, F | 1 |
| Quint, T | 2 |
| Dahm, V | 1 |
| Ramazanova, D | 1 |
| Arnoldner, MA | 1 |
| Kurz, H | 1 |
| Janik, S | 1 |
| Brunner, PM | 1 |
| Knerer-Schally, B | 1 |
| Weninger, W | 1 |
| Griss, J | 1 |
| Ristl, R | 1 |
| Schneider, S | 2 |
| Bangert, C | 2 |
| D'Souza, GE | 1 |
| Nwagu, U | 1 |
| Barton, B | 1 |
| Unsal, AA | 1 |
| Rabinowitz, MR | 1 |
| Rosen, MR | 1 |
| Nyquist, GG | 1 |
| Cohn, J | 1 |
| Most, J | 1 |
| Toskala, EM | 1 |
| Talat, R | 1 |
| Gengler, I | 1 |
| Phillips, KM | 1 |
| Caradonna, DS | 1 |
| Gray, ST | 1 |
| Sedaghat, AR | 1 |
| Tripathi, SH | 1 |
| Kumar, A | 1 |
| Kohanski, MA | 2 |
| Kennedy, DW | 1 |
| Palmer, JN | 1 |
| Adappa, ND | 1 |
| Bosso, JV | 3 |
| Wallace, DV | 1 |
| Laidlaw, TM | 7 |
| Chu, DK | 2 |
| Stevens, WW | 5 |
| Miss Ozuna, L | 1 |
| Ryan, T | 2 |
| Bensko, JC | 3 |
| Buchheit, KM | 8 |
| Sohail, A | 1 |
| Hacker, J | 2 |
| Maurer, R | 3 |
| Gakpo, D | 1 |
| Taliaferro, F | 1 |
| Ordovas-Montanes, J | 1 |
| Aydin, Ö | 1 |
| Atmiş, EÖ | 1 |
| Anadolu, Y | 1 |
| Yorulmaz, İ | 1 |
| Çelik, GE | 1 |
| Walters, BK | 1 |
| Hagan, JB | 1 |
| Divekar, RD | 1 |
| Willson, TJ | 1 |
| Stokken, JK | 1 |
| Pinheiro-Neto, CD | 1 |
| O'Brien, EK | 1 |
| Choby, G | 1 |
| Rank, MA | 1 |
| Bognanni, A | 1 |
| Oykhman, P | 1 |
| Bernstein, JA | 2 |
| Ellis, AK | 1 |
| Golden, DBK | 1 |
| Greenhawt, M | 1 |
| Horner, CC | 1 |
| Ledford, DK | 1 |
| Lieberman, J | 1 |
| Luong, AU | 1 |
| Orlandi, RR | 1 |
| Samant, SA | 1 |
| Shaker, MS | 1 |
| Soler, ZM | 1 |
| Stukus, DR | 1 |
| Wang, J | 1 |
| Peters, AT | 1 |
| Poglitsch, K | 1 |
| Morgenstern, C | 1 |
| Gangl, K | 1 |
| Sinz, C | 1 |
| Bartosik, T | 1 |
| Campion, NJ | 1 |
| Liu, DT | 1 |
| Landegger, LD | 1 |
| Tu, A | 1 |
| Stanek, V | 1 |
| Rocha-Hasler, M | 1 |
| Eckl-Dorna, J | 1 |
| Perić, A | 3 |
| Gaćeša, D | 2 |
| Cvetković, G | 1 |
| Vojvodić, D | 1 |
| Cahill, KN | 4 |
| Alfallaj, R | 1 |
| Obaid, SB | 1 |
| Almousa, H | 1 |
| Ismail, D | 1 |
| Mahjoub, S | 1 |
| Alanazy, F | 1 |
| Dousary, SA | 1 |
| Alromaih, S | 1 |
| Aloulah, M | 1 |
| Alrasheed, A | 1 |
| Alroqi, AS | 1 |
| Alsaleh, S | 1 |
| Mullur, J | 1 |
| McGill, A | 1 |
| Supron, AD | 1 |
| Bergmark, RW | 2 |
| Roditi, RE | 1 |
| Adame, MJ | 1 |
| Raji, M | 1 |
| Shan, Y | 1 |
| Zhang, Y | 1 |
| Kuo, YF | 1 |
| Tripple, JW | 1 |
| Vukadinović, T | 1 |
| Vuksanović Božarić, A | 1 |
| Vukomanović Đurđević, B | 1 |
| Radunović, M | 1 |
| San Nicoló, M | 1 |
| Högerle, C | 1 |
| Gellrich, D | 1 |
| Eder, K | 1 |
| Pfrogner, E | 1 |
| Larivée, N | 1 |
| Chin, CJ | 1 |
| Hahn, J | 1 |
| Appel, H | 1 |
| Scheithauer, MO | 1 |
| Petereit, F | 1 |
| Greve, J | 1 |
| Lindemann, J | 1 |
| Hoffmann, TK | 1 |
| Veit, JA | 1 |
| Sommer, F | 1 |
| Alanin, MC | 1 |
| Laidlaw, T | 2 |
| Society, TS | 1 |
| Hopkins, C | 4 |
| McHugh, T | 1 |
| Levin, M | 1 |
| Snidvongs, K | 1 |
| Banglawala, SM | 1 |
| Sommer, DD | 2 |
| Grose, E | 1 |
| Lee, DJ | 1 |
| Yip, J | 1 |
| Cottrell, J | 1 |
| Sykes, J | 1 |
| Lee, JK | 1 |
| Lee, JM | 1 |
| Malfitano, MJ | 1 |
| Santarelli, GD | 1 |
| Gelpi, M | 1 |
| Brown, WC | 1 |
| Stepp, WH | 1 |
| Hernandez, S | 1 |
| Kimple, AJ | 1 |
| Thorp, BD | 1 |
| Zanation, AM | 1 |
| Ebert, CS | 1 |
| Jakiela, B | 1 |
| Soja, J | 1 |
| Sladek, K | 1 |
| Przybyszowski, M | 1 |
| Plutecka, H | 2 |
| Gielicz, A | 3 |
| Rebane, A | 1 |
| Bochenek, G | 3 |
| Mustafa, SS | 1 |
| Vadamalai, K | 1 |
| Scott, B | 1 |
| Ramsey, A | 1 |
| Jerschow, E | 2 |
| Baptist, AP | 1 |
| Borish, L | 2 |
| Campo, P | 1 |
| Cho, SH | 1 |
| Keswani, A | 1 |
| Levy, JM | 3 |
| Nanda, A | 1 |
| Palumbo, M | 1 |
| Rahman, S | 1 |
| Dominas, C | 1 |
| Roditi, R | 1 |
| Bhattacharyya, N | 1 |
| Maxfield, A | 1 |
| Espersen, J | 1 |
| Weber, U | 1 |
| Römer-Franz, A | 1 |
| Lenarz, T | 1 |
| Stolle, SRO | 1 |
| Warnecke, A | 1 |
| Cook, KA | 2 |
| Domissy, A | 1 |
| Simon, RA | 11 |
| Modena, BD | 1 |
| White, A | 1 |
| Arshi, S | 2 |
| Darougar, S | 1 |
| Nabavi, M | 2 |
| Bemanian, MH | 2 |
| Fallahpour, M | 2 |
| Shokri, S | 1 |
| Ahmadian, J | 1 |
| Molatefi, R | 1 |
| Rekabi, M | 1 |
| Moinfar, Z | 1 |
| Hashemitari, P | 1 |
| Eslami, N | 1 |
| Sehanobish, E | 1 |
| Asad, M | 1 |
| Barbi, M | 1 |
| Porcelli, SA | 1 |
| Yong, M | 1 |
| Wu, YQ | 1 |
| Howlett, J | 1 |
| Ballreich, J | 1 |
| Walgama, E | 1 |
| Thamboo, A | 1 |
| Cohen, NA | 1 |
| Barrett, NA | 1 |
| Rodríguez-Jiménez, JC | 1 |
| Moreno-Paz, FJ | 1 |
| Terán, LM | 1 |
| Guaní-Guerra, E | 1 |
| Walters, KM | 1 |
| Waldram, JD | 3 |
| Woessner, KM | 3 |
| Philpott, CM | 1 |
| Erskine, S | 2 |
| Kumar, N | 2 |
| Anari, S | 2 |
| Kara, N | 2 |
| Sunkaraneni, S | 1 |
| Ray, J | 2 |
| Clark, A | 2 |
| Wilson, A | 1 |
| Philpott, C | 1 |
| Robertson, A | 1 |
| Ahmed, S | 1 |
| Carrie, S | 1 |
| Sunkaraneni, V | 1 |
| Jervis, P | 1 |
| Panesaar, J | 1 |
| Farboud, A | 1 |
| Cathcart, R | 1 |
| Almeyda, R | 1 |
| Khalil, H | 1 |
| Prinsley, P | 1 |
| Mansell, N | 1 |
| Salam, M | 1 |
| Hobson, J | 1 |
| Woods, J | 1 |
| Coombes, E | 1 |
| Yamaguchi, T | 1 |
| Ishii, T | 2 |
| Yamamoto, K | 1 |
| Higashi, N | 3 |
| Taniguchi, M | 3 |
| Okamoto, M | 1 |
| Weinstein, SF | 1 |
| Katial, RK | 3 |
| Bardin, P | 1 |
| Korn, S | 1 |
| McDonald, M | 1 |
| Garin, M | 1 |
| Bateman, ED | 1 |
| Hoyte, FCL | 1 |
| Germinaro, M | 1 |
| Eid, RC | 1 |
| Palumbo, ML | 1 |
| DeGregorio, GA | 1 |
| Singer, J | 1 |
| Doña, I | 1 |
| Barrionuevo, E | 1 |
| Salas, M | 1 |
| Laguna, JJ | 1 |
| Agúndez, J | 1 |
| García-Martín, E | 1 |
| Bogas, G | 1 |
| Perkins, JR | 1 |
| Cornejo-García, JA | 1 |
| Torres, MJ | 1 |
| Kowalski, ML | 8 |
| Cooper, T | 1 |
| Greig, SR | 1 |
| Zhang, H | 1 |
| Seemann, R | 1 |
| Wright, ED | 1 |
| Vliagoftis, H | 1 |
| Côté, DWJ | 1 |
| Kovačević, SV | 1 |
| Barać, A | 1 |
| Perić, AV | 1 |
| Jožin, SM | 1 |
| Förster-Ruhrmann, U | 1 |
| Behrbohm, W | 1 |
| Pierchalla, G | 1 |
| Szczepek, AJ | 1 |
| Fluhr, JW | 1 |
| Olze, H | 1 |
| Cleland, EJ | 1 |
| Bassiouni, A | 1 |
| Wormald, PJ | 2 |
| Mullol, J | 4 |
| Picado, C | 5 |
| Karakaya, G | 1 |
| Celebioglu, E | 1 |
| Kalyoncu, AF | 1 |
| Jang, DW | 1 |
| Comer, BT | 1 |
| Lachanas, VA | 1 |
| Kountakis, SE | 3 |
| Miller, B | 1 |
| Mirakian, R | 2 |
| Gane, S | 1 |
| Larco, J | 1 |
| Sannah, AA | 1 |
| Darby, Y | 1 |
| Scadding, G | 3 |
| Kutlu, A | 1 |
| Salihoglu, M | 1 |
| Haholu, A | 1 |
| Cesmeci, E | 1 |
| Cincik, H | 1 |
| Ozturk, S | 1 |
| Edward, JA | 1 |
| Sanyal, M | 1 |
| Ramakrishnan, VR | 2 |
| Le, W | 1 |
| Nguyen, AL | 1 |
| Kingdom, TT | 3 |
| Hwang, PH | 2 |
| Nayak, JV | 2 |
| Klimek, L | 1 |
| Dollner, R | 1 |
| Pfaar, O | 1 |
| Parikh, A | 3 |
| Scadding, GK | 2 |
| Świerczyńska-Krępa, M | 2 |
| Sanak, M | 5 |
| Stręk, P | 2 |
| Ćmiel, A | 1 |
| Szczeklik, A | 7 |
| Niżankowska-Mogilnicka, E | 4 |
| Montone, KT | 1 |
| Cho, KS | 1 |
| Soudry, E | 1 |
| Psaltis, AJ | 1 |
| Nadeau, KC | 1 |
| McGhee, SA | 1 |
| Machado-Carvalho, L | 1 |
| Roca-Ferrer, J | 2 |
| Hoffbauer, S | 1 |
| Au, M | 1 |
| Sowerby, LJ | 2 |
| Gupta, MK | 1 |
| Nayan, S | 1 |
| Dazy, KM | 2 |
| Matsusaka, M | 1 |
| Kabata, H | 1 |
| Fukunaga, K | 1 |
| Suzuki, Y | 1 |
| Masaki, K | 1 |
| Mochimaru, T | 1 |
| Sakamaki, F | 1 |
| Oyamada, Y | 1 |
| Inoue, T | 1 |
| Oguma, T | 1 |
| Sayama, K | 1 |
| Koh, H | 1 |
| Nakamura, M | 1 |
| Umeda, A | 1 |
| Ono, J | 1 |
| Ohta, S | 1 |
| Izuhara, K | 1 |
| Asano, K | 1 |
| Betsuyaku, T | 1 |
| DeConde, AS | 1 |
| Suh, JD | 1 |
| Mace, JC | 1 |
| Alt, JA | 1 |
| Smith, TL | 3 |
| Esmaeilzadeh, H | 1 |
| Aryan, Z | 1 |
| Mortazavi, N | 1 |
| Makowska, J | 1 |
| Lewandowska-Polak, A | 1 |
| Wojtczak, A | 1 |
| Skrętkowicz, J | 1 |
| Szabó, K | 1 |
| Polyánka, H | 1 |
| Kiricsi, Á | 1 |
| Révész, M | 1 |
| Vóna, I | 1 |
| Szabó, Z | 2 |
| Bella, Z | 1 |
| Kadocsa, E | 1 |
| Kemény, L | 1 |
| Széll, M | 1 |
| Hirschberg, A | 1 |
| Pezato, R | 1 |
| Holtappels, G | 2 |
| De Ruyck, N | 1 |
| Derycke, L | 1 |
| Van Crombruggen, K | 1 |
| Bachert, C | 5 |
| Pérez-Novo, CA | 1 |
| Zhang, L | 1 |
| Gevaert, P | 3 |
| Gitomer, SA | 1 |
| Fountain, CR | 1 |
| Getz, AE | 1 |
| Sillau, SH | 1 |
| Adelman, J | 1 |
| McLean, C | 1 |
| Shaigany, K | 1 |
| Krouse, JH | 1 |
| Dunn, NM | 1 |
| Fruth, K | 2 |
| Gosepath, J | 4 |
| Sakalar, EG | 1 |
| Muluk, NB | 1 |
| Kar, M | 1 |
| Cingi, C | 1 |
| Schleimer, RP | 1 |
| Stevenson, DD | 10 |
| Gudziol, V | 2 |
| Michel, M | 1 |
| Sonnefeld, C | 1 |
| Koschel, D | 1 |
| Hummel, T | 2 |
| Scott, JR | 1 |
| Ernst, HM | 1 |
| Rotenberg, BW | 1 |
| Rudmik, L | 1 |
| Williams, AN | 1 |
| Yoshimura, T | 1 |
| Yoshikawa, M | 1 |
| Otori, N | 1 |
| Haruna, S | 1 |
| Moriyama, H | 1 |
| Caversaccio, M | 1 |
| Häusler, R | 1 |
| Helbling, A | 1 |
| Das, S | 1 |
| Maeso, PA | 1 |
| Becker, AM | 1 |
| Prosser, JD | 1 |
| Adam, BL | 1 |
| Platt, M | 1 |
| Metson, R | 1 |
| Stankovic, K | 1 |
| Jung, H | 1 |
| Di Leo, E | 1 |
| Nettis, E | 1 |
| Calogiuri, GF | 1 |
| Ferrannini, A | 1 |
| Vacca, A | 1 |
| Cardona, R | 1 |
| Ramírez, RH | 1 |
| Reina, Z | 1 |
| Escobar, MF | 1 |
| Morales, E | 1 |
| Schachtel, BP | 1 |
| Voelker, M | 1 |
| Sanner, KM | 1 |
| Gagney, D | 1 |
| Bey, M | 1 |
| Schachtel, EJ | 1 |
| Becka, M | 1 |
| Ryan, MW | 2 |
| Brooks, EG | 1 |
| Wood, AJ | 1 |
| Douglas, RG | 1 |
| Rizk, H | 1 |
| Riabova, MA | 1 |
| Shumilova, NA | 1 |
| Merkonidis, C | 1 |
| Cecchini, MP | 1 |
| Gerber, J | 1 |
| Seo, HS | 1 |
| Goebel, G | 1 |
| Koutsimpelas, D | 1 |
| Schmidtmann, I | 1 |
| Mann, WJ | 3 |
| Brieger, J | 1 |
| Celejewska-Wójcik, N | 1 |
| Mastalerz, L | 2 |
| Wójcik, K | 1 |
| Nieckarz, R | 1 |
| Januszek, R | 1 |
| Hartwich, P | 1 |
| Szaleniec, J | 1 |
| Hydzik-Sobocińska, K | 1 |
| Oleś, K | 1 |
| Cybulska, A | 1 |
| Shikani, AH | 1 |
| Kourelis, K | 1 |
| Rohayem, Z | 1 |
| Basaraba, RJ | 1 |
| Leid, JG | 1 |
| Mita, H | 2 |
| Osame, M | 2 |
| Akiyama, K | 2 |
| Berges-Gimeno, MP | 3 |
| Namazy, JA | 1 |
| Paganin, F | 1 |
| Poubeau, P | 1 |
| Yvin, JL | 1 |
| Arvin-Berod, C | 1 |
| DUGAS, M | 1 |
| MILLER, J | 1 |
| ABRUZZI, WA | 1 |
| DE VARENNE, D | 1 |
| Fox, RW | 1 |
| Lockey, RF | 2 |
| Bánska, K | 1 |
| Nizankowska, E | 3 |
| Swierczynska, M | 2 |
| Zarychta, J | 1 |
| Groneberg, DA | 1 |
| Heppt, W | 1 |
| Welker, P | 1 |
| Peiser, C | 1 |
| Dinh, QT | 1 |
| Cryer, A | 1 |
| Zweng, M | 1 |
| Witt, C | 1 |
| Fischer, A | 1 |
| Kiełbasa, B | 1 |
| Kawagishi, Y | 1 |
| Higashi, A | 1 |
| Pujols, L | 1 |
| Alobid, I | 1 |
| Xaubet, A | 1 |
| Van Zele, T | 2 |
| Watelet, JB | 1 |
| Claeys, G | 1 |
| Claeys, C | 1 |
| van Cauwenberge, P | 2 |
| Gollapudi, RR | 1 |
| Teirstein, PS | 1 |
| Corrigan, C | 1 |
| Mallett, K | 1 |
| Ying, S | 2 |
| Roberts, D | 1 |
| Lee, T | 1 |
| Celik, G | 2 |
| Paşaoğlu, G | 1 |
| Bavbek, S | 2 |
| Abadoğlu, O | 1 |
| Dursun, B | 1 |
| Mungan, D | 2 |
| Misirligil, Z | 2 |
| Cormican, LJ | 1 |
| Farooque, S | 1 |
| Altmann, DR | 1 |
| Lee, TH | 3 |
| Ptasinska, A | 1 |
| Jedrzejczak, M | 1 |
| Bienkiewicz, B | 2 |
| Cieslak, M | 1 |
| Grzegorczyk, J | 2 |
| Pawliczak, R | 2 |
| Dubuske, L | 1 |
| de Weck, A | 1 |
| Sanz, ML | 1 |
| Gamboa, P | 1 |
| Meng, Q | 1 |
| Corrigan, CJ | 1 |
| Micheletto, C | 1 |
| Visconti, M | 1 |
| Tognella, S | 1 |
| Facchini, FM | 1 |
| Dal Negro, RW | 1 |
| Lee, JY | 1 |
| Sok, JC | 2 |
| Ferguson, BJ | 2 |
| Owens, JM | 1 |
| Shroyer, KR | 1 |
| Modrzyński, M | 1 |
| Mazurek, H | 1 |
| Zawisza, E | 1 |
| Kim, SH | 1 |
| Park, HS | 1 |
| Holloway, JW | 1 |
| Shin, HD | 1 |
| Park, CS | 1 |
| Specjalski, K | 1 |
| Chełmińska, M | 1 |
| Smith, WB | 1 |
| Magnan, A | 1 |
| Macy, E | 1 |
| Castells, MC | 1 |
| Gawchik, SM | 1 |
| Settipane, RA | 1 |
| Wald, J | 1 |
| Robinson, JL | 1 |
| Griest, S | 1 |
| James, KE | 1 |
| Zhang, N | 1 |
| Patou, J | 1 |
| Slavin, RG | 1 |
| Kim, JE | 1 |
| Browne, JP | 1 |
| Slack, R | 1 |
| Lund, V | 1 |
| Brown, P | 1 |
| Durham, SR | 1 |
| Jones, NS | 1 |
| Drake-Lee, AB | 1 |
| Ryan, D | 1 |
| Dixon, TA | 1 |
| Huber, PA | 1 |
| Nasser, SM | 1 |
| Salib, RJ | 1 |
| Harries, PG | 1 |
| Nair, SB | 1 |
| Howarth, PH | 1 |
| Joe, SA | 1 |
| Thakkar, K | 1 |
| Settipane, GA | 3 |
| Pleskow, WW | 1 |
| Mathison, DA | 3 |
| Lumry, WR | 2 |
| Schatz, M | 1 |
| Zeiger, RS | 1 |
| Curd, JG | 1 |
| Scherrer, M | 1 |
| Zeller, C | 1 |
| Berger, M | 1 |
| Enzmann, H | 1 |
| Rieben, FW | 1 |
| Tan, Y | 1 |
| Collins-Williams, C | 1 |
| Rosenhall, L | 1 |
| Saldi, M | 1 |
| Swierczyński, Z | 1 |
| Samoliński, B | 1 |
| Krzeski, A | 1 |
| Sliwinska-Kowalska, M | 1 |
| Igarashi, Y | 1 |
| White, MV | 1 |
| Wojciechowska, B | 1 |
| Brayton, P | 1 |
| Kaulbach, H | 1 |
| Rozniecki, J | 1 |
| Kaliner, MA | 1 |
| Jankowski, R | 2 |
| Senna, GE | 1 |
| Passalacqua, G | 1 |
| Andri, G | 1 |
| Dama, AR | 1 |
| Albano, M | 1 |
| Fregonese, L | 1 |
| Andri, L | 1 |
| Sánchez-Borges, M | 1 |
| Capriles-Hulett, A | 1 |
| Capriles-Behrens, E | 1 |
| Fernandez-Caldas, E | 1 |
| Milewski, M | 1 |
| Duplaga, M | 1 |
| Kaliner, M | 1 |
| Atamuradov, MA | 1 |
| Garaev, TA | 1 |
| Sturtevant, J | 1 |
| Ediger, D | 1 |
| Demirel, YS | 1 |
| Kordek, P | 1 |
| Studniarek, M | 1 |
| Kośny, B | 1 |
| Casadevall, J | 1 |
| Ventura, PJ | 1 |
| May, A | 1 |
| Wagner, D | 1 |
| Langenbeck, U | 1 |
| Weber, A | 1 |
| Babu, KS | 1 |
| Salvi, SS | 1 |
| Schaefer, D | 1 |
| Amedee, RG | 1 |
| Mardiney, M | 1 |
| Kornatowski, T | 1 |
| Wagrowska-Danilewicz, M | 1 |
| Danilewicz, M | 1 |
| Mygind, N | 1 |
| Gorenberg, D | 1 |
| Lewis, DP | 1 |
| Casterline, CL | 2 |
| Stein, M | 1 |
| Vedanthan, PK | 1 |
| Menon, MM | 1 |
| Bell, TD | 1 |
| Bergin, D | 1 |
| Faidi, AR | 1 |
| Gryglewski, RJ | 1 |
| Czerniawska-Mysik, G | 1 |
| Stenius, BS | 1 |
| Lemola, M | 1 |
| Probst, L | 1 |
| Stoney, P | 1 |
| Jeney, E | 1 |
| Hawke, M | 1 |
| Schwartz, LB | 1 |
| Pawlowicz, A | 1 |
| Williams, WR | 1 |
| Davies, BH | 1 |
| Sweet, JM | 1 |
| Moneret-Vautrin, DA | 2 |
| Hsieh, V | 2 |
| Wayoff, M | 2 |
| Guyot, JL | 1 |
| Mouton, C | 1 |
| Maria, Y | 2 |
| Knight, A | 1 |
| Ogino, S | 1 |
| Harada, T | 1 |
| Matsunaga, T | 1 |
| Okawachi, I | 1 |
| Irifune, M | 1 |
| Nagano, T | 1 |
| Gorichkina, LA | 1 |
| Frolova, MK | 1 |
| Kuria, VF | 1 |
| Blue, JA | 1 |
| Rucknagel, DL | 1 |
| Vanselow, NA | 1 |
| Marcoux, J | 1 |
| Labbé, J | 1 |
| Michaëlsson, G | 1 |
| Juhlin, L | 1 |
| Fisherman, EW | 2 |
| Cohen, GN | 2 |
| Samter, M | 1 |
| Beers, RF | 1 |
| Hawkins, D | 1 |
| Pinckard, RN | 1 |
| Farr, RS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Moving Towards PREcision Medicine In United Airways Disease: Unraveling inflaMmatory Patterns in Asthmatic Patients With or Without Nasal Polyps (PREMIUM) - a Descriptive Pilot Study[NCT05009758] | 30 participants (Anticipated) | Interventional | 2021-09-01 | Recruiting | |||
| A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma[NCT01287039] | Phase 3 | 489 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma[NCT01285323] | Phase 3 | 464 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Dupilumab as add-on Therapy for Aspirin-exacerbated Respiratory Disease (AERD)[NCT03595488] | Phase 2 | 11 participants (Actual) | Interventional | 2018-09-05 | Completed | ||
| Improving Patient Care Via Proteomics Based, Microbe-Specific Detection of Chronic Rhinosinusitis[NCT00962689] | 38 participants (Actual) | Observational | 2009-08-31 | Completed | |||
| Gel-Sinuplasty for Chronic Rhinosinusitis With and Without Nasal Polyposis[NCT03472144] | Phase 3 | 60 participants (Anticipated) | Interventional | 2017-07-07 | Recruiting | ||
| The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases[NCT01867281] | Phase 4 | 32 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Role of Doxycycline in the Management of Patients With Chronic Rhinosinusitis With Nasal Polyps[NCT05157412] | Phase 3 | 60 participants (Anticipated) | Interventional | 2022-03-01 | Not yet recruiting | ||
| Challenge Test for Acetylsalicylic Acid Hypersensitivity[NCT01681615] | 50 participants (Anticipated) | Interventional | 2012-09-30 | Not yet recruiting | |||
| Determinants of Surgical Outcomes in Chronic Sinusitis[NCT00799097] | 516 participants (Actual) | Observational | 2004-07-31 | Completed | |||
| Effect of Thymoquinone and Olive Oil on Wound Healing After Endoscopic Sinus Surgery in Patients With Nasal Polyposis[NCT06070311] | 50 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | |||
| Role of Short Term Systemic Corticosteroid Therapy in the Management of Chronic Rhinosinusitis Without Nasal Polyps[NCT01676415] | Phase 4 | 9 participants (Actual) | Interventional | 2012-08-31 | Terminated (stopped due to participants are no longer receiving intervention due to clinical logistics) | ||
| High Volume Saline Irrigation in the Post-operative Management of Chronic Rhinosinusitis: A Multicenter Randomized Single-Blind Controlled Trial[NCT02636959] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | ||
| Role of Epithelial Barrier Integrity in Biologic Treatment Response of Severe Asthmatics With/Out Chronic Rhinosinusitis With Nasal Polyps (CRSwNP). Can Shedding of Epithelial Barrier Proteins be Used as Biomarker in Severe Asthma With/Out CRSwNP Manageme[NCT05365841] | 85 participants (Anticipated) | Observational | 2022-05-15 | Not yet recruiting | |||
| Ideal Frequency of Postoperative High Volume Saline Irrigations Following Endoscopic Sinus Surgery[NCT01680705] | 75 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| Role of Montelukast in the Management of Chronic Rhinosinusitis With Nasal Polyps.[NCT05143502] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2022-01-01 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The ACQ is a 7-item instrument that measures asthma control (Juniper et al 1999). Six questions are self-assessments; the seventh item, completed by a member of the study staff, is the result of the patient's FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A higher score is an indication of poorer asthma control. The during treatment (Weeks 4, 8, 12 and 16) average ACQ was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline scores indicate improvement in asthma control." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.676 |
| Reslizumab 3.0 mg/kg | -0.941 |
"The AQLQ is a 32-item instrument administered as a self-assessment (Juniper et al 1992). The questionnaire is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Patients were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (1=severe impairment, 7=no impairment). The overall AQLQ score is the mean of all 32 responses. Five of the activity questions were patient-specific, which means that each patient identified and scored 5 activities in which the patient was limited by asthma; these 5 activities were identified at the first visit and retained for all subsequent follow-up visits.~Positive change from baseline scores indicate improvement in quality of life." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Week 16
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.695 |
| Reslizumab 3.0 mg/kg | 0.933 |
"The ASUI is an 11-item instrument designed to assess the frequency and severity of asthma symptoms and side effects, weighted by patient preferences (Revicki et al 1998). ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control; info obtained from questionnaire about asthma symptoms.~The during treatment (Weeks 4, 8, 12 and 16) average ASUI was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Positive change from baseline values indicate improvement in asthma symptoms. Information was obtained from questionnaire about asthma symptoms." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.109 |
| Reslizumab 3.0 mg/kg | 0.167 |
"FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer. Positive change from baseline scores indicate improvement in asthma control.~The during treatment (Weeks 4, 8, 12 and 16) average FEV1 was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16
| Intervention | liters (Least Squares Mean) |
|---|---|
| Placebo | 0.110 |
| Reslizumab 3.0 mg/kg | 0.248 |
"SABA are used for quick relief of asthma symptoms. To measure SABA use, at each clinical visit patients were asked to recall their usage of SABA therapy within the last 3 days of the scheduled visit. If usage was confirmed, the number of puffs used was recorded. For the purpose of summaries, an average daily usage was evaluated by dividing the total number of puffs recorded over 3 days by 3.~The during treatment (Weeks 4, 8, 12 and 16) SABA use was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline scores indicate improvement in asthma control." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16
| Intervention | puffs/day (Least Squares Mean) |
|---|---|
| Placebo | -0.36 |
| Reslizumab 3.0 mg/kg | -0.64 |
"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization CAEs were adjudicated by committee to assure consistency.~Adjusted CAE rate and confidence intervals were based on Negative Binomial regression model adjusted for stratification factors.~Results are offered as adjusted means." (NCT01287039)
Timeframe: Day 1 to Week 52
| Intervention | CAEs in 52 weeks (Mean) |
|---|---|
| Placebo | 1.804 |
| Reslizumab 3.0 mg/kg | 0.904 |
"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.~CAEs were adjudicated by committee to assure consistency. The distributions were compared by a log rank test stratified by baseline usage of oral corticosteroid (yes or no) and geographical region (US or other)." (NCT01287039)
Timeframe: Day 1 to Day 478 (longest treatment time plus 2 weeks)
| Intervention | weeks (Median) |
|---|---|
| Placebo | 34.9 |
| Reslizumab 3.0 mg/kg | NA |
The immunogenicity of reslizumab was assessed by measuring for the presence of anti-reslizumab antibodies at baseline, weeks 16, 32, 48, and 52 or early withdrawal. Blood samples for anti-reslizumab antibodies assessment were also obtained from all patients (inside or outside of the US) experiencing a serious adverse event, an adverse event leading to withdrawal, or an exacerbation of asthma symptoms. (NCT01287039)
Timeframe: Weeks 16, 32, 48 and 52
| Intervention | participants (Number) |
|---|---|
| Reslizumab 3.0 mg/kg | 8 |
"Blood eosinophil counts were measured using a standard complete blood count (CBC) with differential blood test at each scheduled visit, and from all patients experiencing a serious adverse event, an adverse event leading to withdrawal, or an exacerbation of asthma symptoms.~The during treatment average eosinophil counts were estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline values correlate to reduced asthma severity." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 or early withdrawal
| Intervention | 10^9 blood eosinophil/L (Least Squares Mean) | |
|---|---|---|
| Over first 16 weeks | Over 52 weeks | |
| Placebo | -0.118 | -0.127 |
| Reslizumab 3.0 mg/kg | -0.584 | -0.582 |
"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.~CAEs were adjudicated by committee to assure consistency. Adjusted CAE rate and confidence intervals for the two criteria were based on Negative Binomial regression model adjusted for stratification factors.~Results are offered as adjusted means." (NCT01287039)
Timeframe: Day 1 to Week 52
| Intervention | CAEs in 52 weeks (Mean) | |
|---|---|---|
| Requiring systemic corticosterioids >3 days | Requiring hospitalization or ER visit | |
| Placebo | 1.604 | 0.207 |
| Reslizumab 3.0 mg/kg | 0.722 | 0.137 |
An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. (NCT01287039)
Timeframe: Day 1 (post-dose) to Week 65. The last postbaseline value for approximately 20 patients in each
| Intervention | participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| At least 1 AE | Mild severity AE | Moderate severity AE | Severe AE | Treatment-related AE | Treatment-related mild AE | Treatment-related moderate AE | Treatment-related severe AE | AE causing patient discontinuation | Serious AE | Deaths | |
| Placebo | 206 | 41 | 133 | 32 | 36 | 23 | 13 | 0 | 8 | 34 | 1 |
| Reslizumab 3.0 mg/kg | 197 | 68 | 107 | 22 | 36 | 24 | 9 | 3 | 4 | 24 | 0 |
"Data represents participants with potentially clinically significant (PCS) abnormal serum chemistry, hematology, and urinalysis values.~Significance criteria:~Blood urea nitrogen: >=10.71 mmol/L~Uric acid: M>=625, F>=506 μmol/L~Aspartate aminotransferase: >=3*upper limit of normal (ULN). Normal range is 10-43 U/L~Alanine aminotransferase: >=3*ULN. Normal range is 10-40 U/L~GGT = gamma-glutamyl transpeptidase: >= 3*ULN. Normal range is 5-49 U/L.~Bilirubin: >=34.2 μmol/L~White blood cells: <=3.0 or >20 10^9/L~Hemoglobin: M<=115, F<=95 g/dL~Hematocrit: M<0.37, F<0.32 L/L~Neutrophils: <=1.0 10^9/L~Eosinophils: >10.0 %~Platelets: <75 or >=700 10^9/L~Urinalysis: blood, glucose, ketones and total protein: >=2 unit increase from baseline" (NCT01287039)
Timeframe: Week 4 to Week 65. The last postbaseline value for approximately 20 patients in each
| Intervention | participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood urea nitrogen | Uric acid | Aspartate aminotransferase | Alanine aminotransferase | Gamma-glutamyl transpeptidase | Bilirubin | White blood cells - low | White blood cells - high | Hemoglobin | Hematocrit | Neutrophils | Eosinophils | Platelets - low | Platelets - high | Urinalysis - Blood (hemoglobin) | Urinalysis - Ketones | Urinalysis - Glucose | Urinalysis - Protein | |
| Placebo | 9 | 9 | 1 | 3 | 12 | 2 | 6 | 5 | 7 | 9 | 8 | 135 | 1 | 2 | 32 | 4 | 11 | 32 |
| Reslizumab 3.0 mg/kg | 8 | 6 | 1 | 5 | 12 | 1 | 6 | 3 | 4 | 6 | 6 | 3 | 2 | 0 | 21 | 5 | 14 | 34 |
"Data represents participants with potentially clinically significant (PCS) vital sign values.~Significance criteria~Sitting pulse - high 12-17 yr: >100 and increase of >= 30 beats/minute (bpm)~Sitting pulse - low >=18 yr: <50 and decrease of >=30 bpm~Sitting pulse - high >=18 yr: >100 and increase of >=30 bpm~Sitting systolic blood pressure - low >=18 yr: <90 and decrease of >=30 mmHg~Sitting systolic blood pressure - high >=18 yr: >160 and increase of >=30 mmHg~Sitting diastolic blood pressure - low 12-17 yr: <55 and decrease of >=12 mmHg~Sitting diastolic blood pressure - low >=18 yr: <50 and decrease of >=12 mmHg~Sitting diastolic blood pressure - high >=18 yr: >100 and increase of >=12 mmHg~Respiratory rate >=18 yr: >24 and increase of >=10 breaths/minute~Body temperature - low 12-17 yr: <96.5° Fahrenheit or <35.8° Celsius~Body temp - low >=18 yr: <96.5° F or <35.8° C~Body temp - high >=18 yr: >100.5° Fahrenheit" (NCT01287039)
Timeframe: Week 4 to Week 65. The last postbaseline value for approximately 20 patients in each
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sitting pulse - high 12-17 yr | Sitting pulse - low >=18 yr | Sitting pulse - high >=18 yr | Sitting systolic blood pressure - low >=18 yr | Sitting systolic blood pressure - high >=18 yr | Sitting diastolic blood pressure - low 12-17 yr | Sitting diastolic blood pressure - low >=18 yr | Sitting diastolic blood pressure - high >=18 yr | Respiratory rate >=18 yr | Body temperature - low 12-17 yr | Body temperature - low >=18 yr | Body temperature - high >=18 yr | |
| Placebo | 1 | 1 | 5 | 2 | 7 | 1 | 0 | 10 | 3 | 1 | 54 | 0 |
| Reslizumab 3.0 mg/kg | 1 | 0 | 7 | 5 | 7 | 0 | 1 | 5 | 2 | 1 | 49 | 1 |
"The ACQ is a 7-item instrument that measures asthma control (Juniper et al 1999). Six questions are self-assessments; the seventh item, completed by a member of the study staff, is the result of the patient's FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A higher score is an indication of poorer asthma control. The during treatment (Weeks 4, 8, 12 and 16) average ACQ was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline scores indicate improvement in asthma control." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.660 |
| Reslizumab 3.0 mg/kg | -0.857 |
"The AQLQ is a 32-item instrument administered as a self-assessment (Juniper et al 1992). The questionnaire is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Patients were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (1=severe impairment, 7=no impairment). The overall AQLQ score is the mean of all 32 responses. Five of the activity questions were patient-specific, which means that each patient identified and scored 5 activities in which the patient was limited by asthma; these 5 activities were identified at the first visit and retained for all subsequent follow-up visits.~Positive change from baseline scores indicate improvement in quality of life." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Week 16
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.777 |
| Reslizumab 3.0 mg/kg | 0.987 |
"The ASUI is an 11-item instrument designed to assess the frequency and severity of asthma symptoms and side effects, weighted by patient preferences (Revicki et al 1998). ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control; info obtained from questionnaire about asthma symptoms.~The during treatment (Weeks 4, 8, 12 and 16) average ASUI was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Positive change from baseline values indicate improvement in asthma symptoms. Information was obtained from questionnaire about asthma symptoms." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.080 |
| Reslizumab 3.0 mg/kg | 0.115 |
"FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer.~Positive change from baseline scores indicate improvement in asthma control." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Week 16
| Intervention | liters (Least Squares Mean) |
|---|---|
| Placebo | 0.122 |
| Reslizumab 3.0 mg/kg | 0.223 |
"FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer. During study (Weeks 4, 8, 12 and 16) average value used a mixed effect model for repeated measures (MMRM) with treatment group, visit, treatment and visit interaction, and stratification factors as fixed effects and participant as a random effect. Covariates for baseline values were also included in the model; for pulmonary function test analyses, covariates for height and sex were included as well.~Positive change from baseline scores indicate improvement in asthma control." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16
| Intervention | liters (Least Squares Mean) |
|---|---|
| Placebo | 0.094 |
| Reslizumab 3.0 mg/kg | 0.187 |
"SABA are used for quick relief of asthma symptoms. To measure SABA use, at each clinical visit patients were asked to recall their usage of SABA therapy within the last 3 days of the scheduled visit. If usage was confirmed, the number of puffs used was recorded. For the purpose of summaries, an average daily usage was evaluated by dividing the total number of puffs recorded over 3 days by 3.~The during treatment (Weeks 4, 8, 12 and 16) average SABA use was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline scores indicate improvement in asthma control." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16
| Intervention | SABA puffs per day (Least Squares Mean) |
|---|---|
| Placebo | -0.44 |
| Reslizumab 3.0 mg/kg | -0.50 |
"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.~CAEs were adjudicated by committee to assure consistency. Adjusted CAE rate and confidence intervals were based on Negative Binomial regression model adjusted for stratification factors.~Results are offered as adjusted means." (NCT01285323)
Timeframe: Day 1 to Month 12
| Intervention | CAEs in 52 weeks (Mean) |
|---|---|
| Placebo | 2.115 |
| Reslizumab 3.0 mg/kg | 0.859 |
"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.~CAEs were adjudicated by committee to assure consistency. The distributions were compared by a log rank test stratified by baseline usage of oral corticosteroid (yes or no) and geographical region (US or other)." (NCT01285323)
Timeframe: Day 1 to Day 526 (longest treatment time plus 2 weeks)
| Intervention | weeks (Median) |
|---|---|
| Placebo | NA |
| Reslizumab 3.0 mg/kg | NA |
"The blood eosinophil counts were measured using a standard complete blood count (CBC) with differential blood test. Results of all differential blood tests conducted after randomization were blinded.~The during treatment average eosinophil count was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements. The 'over 16 weeks' value used data from Weeks 4, 8, 12 and 16. The 'over 52 weeks' value used all the during study time points listed in the Time Frame field.~Negative change from baseline values correlate to reduced asthma severity." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 or early withdrawal
| Intervention | 10^9 blood eosinophil/L (Least Squares Mean) | |
|---|---|---|
| Over first 16 weeks | Over 52 weeks | |
| Placebo | -0.076 | -0.076 |
| Reslizumab 3.0 mg/kg | -0.555 | -0.565 |
"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization CAEs were adjudicated by committee to assure consistency.~Adjusted CAE rate and confidence intervals for the two criteria were based on Negative Binomial regression model adjusted for stratification factors.~Results are offered as adjusted means." (NCT01285323)
Timeframe: Day 1 to Month 12
| Intervention | CAEs in 52 weeks (Mean) | |
|---|---|---|
| Requiring systemic corticosterioids >3 days | Requiring hospitalization or ER visit | |
| Placebo | 1.660 | 0.047 |
| Reslizumab 3.0 mg/kg | 0.646 | 0.033 |
Counts of participants with a positive anti-drug antibody (ADA) response during treatment is offered for the experimental treatment arm. Blood samples were collected for determination of ADAs before study drug infusion. (NCT01285323)
Timeframe: Baseline visit (prior to reslizumab exposure), Weeks 16, 32, 48 and 52
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Baseline | Week 16 | Week 32 | Week 48 | Week 52 | >=1 positive test result | |
| Reslizumab 3.0 mg/kg | 10 | 10 | 10 | 10 | 10 | 15 |
An adverse event (AE) was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. (NCT01285323)
Timeframe: Day 1 (post-dose) to Week 65. The endpoint for adverse events was the last postbaseline observation, which included the 90 day follow-up visit.
| Intervention | participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Any TEAE | Mild TEAE | Moderate TEAE | Severe TEAE | Treatment-related AE | Mild treatment-related AE | Moderate treatment-related AE | Severe treatment-related AE | TEAE causing patient discontinuation | Deaths | Serious AEs | |
| Placebo | 201 | 36 | 140 | 25 | 27 | 14 | 13 | 0 | 9 | 0 | 23 |
| Reslizumab 3.0 mg/kg | 177 | 67 | 98 | 12 | 34 | 22 | 11 | 1 | 8 | 0 | 18 |
"Data represents participants with potentially clinically significant (PCS) abnormal serum chemistry, hematology (except for eosinophil values), and urinalysis values.~Significance criteria:~Blood urea nitrogen: >=10.71 mmol/L~Creatinine: >=177 μmol/L~Urate: M>=625, F>=506 μmol/L~Aspartate aminotransferase (AST): >=3*upper limit of normal (ULN)~Alanine aminotransferase (ALT): >=3*ULN~GGT = gamma-glutamyl transpeptidase: >= 3*ULN~Total bilirubin: >=34.2 μmol/L~White blood cells (low): <=3.0*10^9/L~White blood cells (high): >=20*10^9/L~Hemoglobin (age >=18 years): M<=115, F<=95 g/dL~Hematocrit (age >=18 years): M<0.37, F<0.32 L/L~Eosinophils/leukocytes: >=10.0%~Platelets: <=75*10^9/L~Neutrophils: <=1.0*10^9/L~Urinalysis: blood, ketones, glucose, and protein: >=2 unit increase from baseline" (NCT01285323)
Timeframe: Week 4 to Week 52
| Intervention | participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood urea nitrogen | Creatinine | Urate | AST | ALT | GGT | Bilirubin | Leukocytes (low) | Leukocytes (high) | Hemoglobin | Hematocrit | Eosinophils/leukocytes | Platelets | Neutrophils | Urine blood (hemoglobin) | Urine ketones | Urine glucose | Urine protein | |
| Placebo | 5 | 0 | 5 | 3 | 7 | 11 | 3 | 3 | 0 | 5 | 10 | 168 | 1 | 14 | 28 | 6 | 9 | 28 |
| Reslizumab 3.0 mg/kg | 4 | 1 | 2 | 2 | 3 | 9 | 3 | 10 | 1 | 6 | 8 | 10 | 1 | 9 | 12 | 1 | 7 | 28 |
"Data represents participants with potentially clinically significant (PCS) vital sign values.~Significance criteria~Sitting pulse (high): >100 and increase of >= 30 beats/minute~Sitting systolic blood pressure (low): <90 and decrease of >= 30 mmHg~Sitting systolic blood pressure (high): >160 and increase of >= 30 mmHg~Sitting diastolic blood pressure (low): <50 and decrease of >=12 mmHg (if 12-17 years old: <55 and decrease of >=12 mmHg 0~Sitting diastolic blood pressure (high): >100 and increase of >=12 mmHg~Respiratory rate (low): <6 breaths/minute~Respiratory rate (high): >24 and increase of >=10 breaths/minute~Body temperature (low): <35.8° Celsius~Body temperature (high): >=38.1 and increase of >=1.1° Celsius" (NCT01285323)
Timeframe: Week 4 to Week 52
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| >=1 postbaseline vital sign abnormality | Sitting pulse (high) | Sitting systolic blood pressure (low) | Sitting systolic blood pressure (high) | Sitting diastolic blood pressure (low) | Sitting diastolic blood pressure (high) | Respiratory rate (low) | Respiratory rate (high) | Body temperature (low) | Body temperature (high) | |
| Placebo | 58 | 6 | 2 | 0 | 4 | 3 | 0 | 4 | 50 | 1 |
| Reslizumab 3.0 mg/kg | 49 | 6 | 1 | 1 | 3 | 4 | 1 | 5 | 39 | 0 |
The medication side-effect and compliance inventory is a questionnaire to evaluate the frequency and severity of common side effects associated with the medications used in this study. (NCT01676415)
Timeframe: 4-6 weeks and 3 months after initiation of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisone | 0 |
| Topical Mometasone | 0 |
Change from baseline in individual symptom severity. The taskforce symptom inventory is a visual analog scale of the severity of the 4 major symptoms making up the clinical diagnostic criteria of CRS. (NCT01676415)
Timeframe: 4-6 weeks and 3 months after initiation of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisone | 0 |
| Topical Mometasone | 0 |
"The Sino-nasal Outcome Test-22 is a validated questionnaire that measures 22 nasal and quality of life symptoms (nasal obstruction and loss of smell and taste) ranked from 0 (not a problem) to 5 (problem as bad as it can be).~Min score= 0, Max score= 110 (worst possible problem on all symptoms)~Change from baseline of the SNOT-22 score. The SNOT-22 questionnaire is a 22-item disease-specific health related quality of life instrument validated for use in chronic rhinosinusitis." (NCT01676415)
Timeframe: 4-6 weeks and 3 months after initiation of treatment
| Intervention | units on a scale (Mean) | |
|---|---|---|
| 4-6 WEEKS | 3 MONTHS | |
| Prednisone | 45.75 | 49 |
| Topical Mometasone | 34.4 | 34.4 |
63 reviews available for aspirin and Nasal Catarrh
| Article | Year |
|---|---|
Treatment options for chronic rhinosinusitis with nasal polyps.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Aspirin; Asthma; Biological Products; Chronic Diseas | 2021 |
Controversies in Allergy: Aspirin Desensitization or Biologics for Aspirin-Exacerbated Respiratory Disease-How to Choose.
Topics: Aspirin; Asthma, Aspirin-Induced; Biological Products; Chronic Disease; Desensitization, Immunologic | 2022 |
Aspirin-Exacerbated Respiratory Disease and the Unified Airway: A Contemporary Review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Chronic Disease; | 2023 |
Aspirin-exacerbated respiratory disease: Updates in the era of biologics.
Topics: Aspirin; Asthma; Asthma, Aspirin-Induced; Biological Products; Chronic Disease; Humans; Nasal Polyps | 2023 |
Aspirin desensitization therapy in aspirin-exacerbated respiratory disease: a systematic review.
Topics: Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Humans; Nasal Polyps; Rhinitis; Sinu | 2020 |
Comorbidities associated with eosinophilic chronic rhinosinusitis: A systematic review and meta-analysis.
Topics: Aspirin; Asthma; Chronic Disease; Comorbidity; Eosinophilia; Humans; Nasal Polyps; Rhinitis; Severit | 2020 |
The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy,
Topics: Administration, Oral; Algorithms; Allergens; Animals; Anti-Inflammatory Agents; Aspirin; Asthma, Asp | 2021 |
Aspirin Actions in Treatment of NSAID-Exacerbated Respiratory Disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, | 2021 |
Aspirin exacerbated respiratory disease: Current topics and trends.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Arachidonic Acid; Aspirin; A | 2018 |
Heterogeneity of NSAID-Exacerbated Respiratory Disease: has the time come for subphenotyping?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Biomarkers; Chronic Disea | 2019 |
Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Hypersensitivity; Humans; Nasal Polyps; Respi | 2013 |
Topical nasal lysine aspirin in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis with nasal polyposis.
Topics: Administration, Intranasal; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Human | 2014 |
The molecular genetics of inflammatory, autoimmune, and infectious diseases of the sinonasal tract: a review.
Topics: Aspirin; Autoimmune Diseases; Churg-Strauss Syndrome; Granulomatosis with Polyangiitis; Humans; Infe | 2014 |
Prostaglandin E2 receptors in asthma and in chronic rhinosinusitis/nasal polyps with and without aspirin hypersensitivity.
Topics: Animals; Aspirin; Asthma; Drug Hypersensitivity; Humans; Nasal Polyps; Receptors, Prostaglandin E, E | 2014 |
Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Desensitization, Immunologic; Hum | 2015 |
Aspirin-exacerbated respiratory disease: characteristics and management strategies.
Topics: Animals; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Humans; Nasal Polyps; Rhini | 2015 |
Hypersensitivity to Aspirin and other NSAIDs: Diagnostic Approach in Patients with Chronic Rhinosinusitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Drug Hypersensitivity; Humans; Rh | 2015 |
[Hypersensitivity to acetylsalicylic acid].
Topics: Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Humans; Incidence; Nasal Polyps; Rhinitis; | 2015 |
Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis.
Topics: Adult; Antibodies, Monoclonal, Humanized; Aspirin; Asthma; Comorbidity; DNA, Catalytic; Drug Hyperse | 2015 |
The Role of Surgery in Management of Samter's Triad: A Systematic Review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Drug Hypersensitivity; Endoscopy; Humans; | 2016 |
Chronic Rhinosinusitis and Aspirin-Exacerbated Respiratory Disease.
Topics: Allergens; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; Disease Progre | 2016 |
Aspirin Exacerbated Respiratory Disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Rhinitis | 2016 |
Aspirin-exacerbated respiratory disease and current treatment modalities.
Topics: Algorithms; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, H | 2017 |
Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Humans; Respiratory Tract Disease | 2016 |
Is aspirin desensitization indicated for the treatment recalcitrant chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease?
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensitization, Immunologic; Humans; Nasal Polyp | 2017 |
Current complications and treatment of aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensit | 2016 |
The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis.
Topics: Administration, Oral; Aspirin; Chronic Disease; Desensitization, Immunologic; Humans; Lysine; Nasal | 2008 |
Gene-expression signatures of nasal polyps associated with chronic rhinosinusitis and aspirin-sensitive asthma.
Topics: Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Gene Expression Profiling; Humans; Nasal Po | 2009 |
[Chronic rhinosinusitis in morbus widal: clinical aspects and therapeutic options].
Topics: Adrenal Cortex Hormones; Aspirin; Asthma; Chronic Disease; Desensitization, Immunologic; Drug Hypers | 2009 |
[Allergy and intolerance to nonsteroidal antinflammatory drugs: successful desensitization in three cases].
Topics: Adult; Anaphylaxis; Angioedema; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspi | 2009 |
Rhinosinusitis and comorbidities.
Topics: Anti-Bacterial Agents; Aspirin; Cystic Fibrosis; Humans; Hypersensitivity; Immunity, Humoral; Immuno | 2010 |
Pathogenesis and treatment of chronic rhinosinusitis.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bi | 2010 |
Role of aspirin desensitization in the management of chronic rhinosinusitis.
Topics: Aspirin; Chronic Disease; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Nasal Polyps; | 2011 |
Aspirin intolerance and nasal polyposis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Hypersensitivity; Eicosanoids; Eosinophils; H | 2002 |
Sensitivity to nonsteroidal anti-inflammatory drugs.
Topics: Acetaminophen; Adult; Anaphylaxis; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bleedin | 2002 |
The impact of rhinosinusitis on asthma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Common Cold; Humans; Rhinitis; Rhinitis, A | 2003 |
Diagnosis, prevention and treatment of aspirin-induced asthma and rhinitis.
Topics: Aspirin; Asthma; Cyclooxygenase Inhibitors; Humans; Leukotrienes; Prostaglandin-Endoperoxide Synthas | 2002 |
Aspirin intolerance and the cyclooxygenase-leukotriene pathways.
Topics: Aspirin; Asthma; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Desensiti | 2004 |
Nonsteroidal anti-inflammatory drug-induced reactions and desensitization.
Topics: Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cross Reactions; Cyclooxygenas | 2004 |
Aspirin sensitivity: implications for patients with coronary artery disease.
Topics: Algorithms; Anaphylaxis; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Coron | 2004 |
Current concepts in therapy of chronic rhinosinusitis and nasal polyposis.
Topics: Anti-Bacterial Agents; Antifungal Agents; Aspirin; Chronic Disease; Endoscopy; Eosinophilia; Histami | 2005 |
Differential diagnosis of eosinophilic chronic rhinosinusitis.
Topics: Animals; Aspirin; Chronic Disease; Diagnosis, Differential; Eosinophilia; Fungi; Humans; Hypersensit | 2006 |
[Diagnosis and treatment of aspirin-induced asthma].
Topics: Aspirin; Asthma; Bronchial Provocation Tests; Desensitization, Immunologic; Dose-Response Relationsh | 2006 |
[Allergy to non steroidal anti-inflammatory drugs].
Topics: Anaphylaxis; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Provoca | 2006 |
Differential diagnosis of eosinophilic chronic rhinosinusitis.
Topics: Aspirin; Chronic Disease; Diagnosis, Differential; Eosinophilia; Eosinophils; Humans; Mycoses; Rhini | 2007 |
Aspirin-sensitive rhinosinusitis and asthma.
Topics: Arachidonic Acid; Aspirin; Asthma; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Infl | 2007 |
Staphylococcus aureus enterotoxins as immune stimulants in chronic rhinosinusitis.
Topics: Animals; Aspirin; Chronic Disease; Enterotoxins; Humans; Immunoglobulin E; Mice; Nasal Mucosa; Nasal | 2007 |
Medical management of rhinosinusitis comorbidities-asthma, aspirin sensitivity, gastroesophageal reflux, immune deficiencies.
Topics: Aspirin; Asthma; Drug Hypersensitivity; Eosinophils; Gastroesophageal Reflux; Humans; Immunologic De | 2007 |
Mechanisms and mediators of nasal symptoms in non-allergic rhinitis.
Topics: Administration, Topical; Air; Aspirin; Cold Temperature; Food; Hormones; Humans; Nasal Decongestants | 2008 |
Chronic rhinosinusitis and asthma.
Topics: Aspirin; Asthma; Chronic Disease; Comorbidity; Drug Hypersensitivity; Humans; Lymphocytes; Nasal Muc | 2008 |
Diseases associated with chronic rhinosinusitis: what is the significance?
Topics: Aspirin; Chronic Disease; Cystic Fibrosis; Humans; Hypersensitivity; Immunocompromised Host; Inciden | 2008 |
Aspirin and allergic diseases: a review.
Topics: Aspirin; Asthma; Bronchial Spasm; Cross Reactions; Desensitization, Immunologic; Drug Hypersensitivi | 1983 |
[The classification of nonallergic eosinophilic rhinitis and sinus].
Topics: Age Factors; Aspirin; Asthma; Drug Tolerance; Eosinophils; Humans; Nasal Polyps; Neutrophils; Rhinit | 1994 |
Eosinophils in the pathophysiology of nasal polyposis.
Topics: Antigens, CD; Aspirin; Eosinophils; Fibroblasts; Granulocyte-Macrophage Colony-Stimulating Factor; H | 1996 |
Nimesulide in the treatment of patients intolerant of aspirin and other NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Humans; Rhinitis; Sulfonamides | 1996 |
A new triad: sensitivity to aspirin, allergic rhinitis, and severe allergic reaction to ingested aeroallergens.
Topics: Adolescent; Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Hypersensitivity; | 1997 |
Rhinosinusitis and nasal polyposis in aspirin sensitive and aspirin tolerant patients: are they different?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Humans; Nasal Polyps; R | 2000 |
Aspirin and asthma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acids; Aspirin; Asthma; Bronchial Hyperreactivi | 2000 |
Aspirin-induced rhinitis and asthma.
Topics: Aspirin; Asthma; Eicosanoids; Glutathione Transferase; Humans; Rhinitis; Sinusitis | 2001 |
Immunohistopathology of allergic rhinitis and conditions allied.
Topics: Antigen-Antibody Reactions; Aspirin; Drug Tolerance; Eosinophils; Epithelium; Epitopes; Humans; Immu | 1978 |
Tartrazine sensitivity and aspirin intolerance.
Topics: Aspirin; Azo Compounds; Bronchial Spasm; Cross Reactions; Drug Hypersensitivity; Humans; Rhinitis; T | 1977 |
Nasal polyps, bronchial asthma and aspirin sensitivity.
Topics: Aspirin; Asthma; Drug Hypersensitivity; Humans; Nasal Polyps; Rhinitis; Syndrome | 1992 |
Desensitization to aspirin in aspirin-sensitive patients with rhino-sinusitis and asthma: a review.
Topics: Aspirin; Asthma; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Nasal Polyps; Rhinitis | 1989 |
20 trials available for aspirin and Nasal Catarrh
| Article | Year |
|---|---|
Dupilumab as Add-on Therapy for Chronic Rhinosinusitis With Nasal Polyposis in Aspirin Exacerbated Respiratory Disease.
Topics: Antibodies, Monoclonal, Humanized; Aspirin; Chronic Disease; Humans; Nasal Polyps; Quality of Life; | 2021 |
The Effect of Aspirin on Moderate to Severe Asthmatic Patients with Aspirin Hypersensitivity, Chronic Rhinosinusitis, and Nasal Polyposis.
Topics: Adult; Anti-Asthmatic Agents; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Double-Blind Method | 2021 |
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2019 |
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2019 |
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2019 |
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2019 |
Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery.
Topics: Adult; Aspirin; China; Chronic Disease; Double-Blind Method; Endoscopy; Female; Humans; Male; Middle | 2019 |
Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study.
Topics: Administration, Oral; Adult; Aged; Allergens; Aspirin; Asthma; Asthma, Aspirin-Induced; Chronic Dise | 2014 |
Treatment of aspirin exacerbated respiratory disease with a low salicylate diet: a pilot crossover study.
Topics: Adult; Aged; Aspirin; Asthma; Cross-Over Studies; Desensitization, Immunologic; Drug Hypersensitivit | 2015 |
Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, I | 2015 |
Systemic expression of inflammatory mediators in patients with chronic rhinosinusitis and nasal polyps with and without Aspirin Exacerbated Respiratory Disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; C | 2016 |
Demonstration of the analgesic efficacy and dose-response of acetylsalicylic acid with pseudoephedrine.
Topics: Adolescent; Adult; Analgesics, Non-Narcotic; Aspirin; Common Cold; Dose-Response Relationship, Drug; | 2010 |
Topical gel therapy for sinonasal polyposis in Samter's triad: preliminary report.
Topics: Administration, Topical; Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Aspirin; Asth | 2012 |
[The effectiveness of leukotriene antagonists in the treatment of aspirin-intolerant asthmatic patients].
Topics: Acetates; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bleeding Time; Cyclopropa | 2003 |
Nasal versus bronchial and nasal response to oral aspirin challenge: Clinical and biochemical differences between patients with aspirin-induced asthma/rhinitis.
Topics: Administration, Oral; Adult; Aspirin; Asthma; Bronchi; Dinoprost; Female; Humans; Leukotriene E4; Ma | 2003 |
Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance.
Topics: Adult; Anaphylaxis; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bronchial Spasm; Celecoxib; Cy | 2005 |
[Nasal provocation test with lysine-aspirin in diagnosis of nonallergic rhinitis with eosinophilia].
Topics: Administration, Intranasal; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; D | 2006 |
Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin.
Topics: Aspirin; Asthma; Clinical Trials as Topic; Double-Blind Method; Drug Hypersensitivity; Forced Expira | 1984 |
Intranasal fluticasone propionate for chronic eosinophilic rhinitis in patients with aspirin-induced asthma.
Topics: Administration, Intranasal; Adult; Androstadienes; Anti-Allergic Agents; Aspirin; Asthma; Chronic Di | 1997 |
The use of nimesulide in patients with acetylsalicylic acid and nonsteroidal anti-inflammatory drug intolerance.
Topics: Administration, Oral; Adult; Aged; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ast | 1999 |
[Point scale quantification of changes in computed tomography of chronic hyperplastic rhinosinusitis].
Topics: Adult; Aspirin; Chronic Disease; Humans; Image Processing, Computer-Assisted; Middle Aged; Paranasal | 2000 |
Aspirin and tartrazine oral challenge: incidence of adverse response in chronic childhood asthma.
Topics: Adolescent; Aspirin; Asthma; Azo Compounds; Blood Pressure; Child; Chronic Disease; Clinical Trials | 1977 |
Hypersensitivity to acetylsalicylic acid (ASA) and tartrazine in patients with asthma.
Topics: Adolescent; Adult; Aged; Aging; Airway Obstruction; Aspirin; Asthma; Azo Compounds; Benzenesulfonate | 1976 |
122 other studies available for aspirin and Nasal Catarrh
| Article | Year |
|---|---|
Appraisal of the Real-World Effectiveness of Biologic Therapies in Aspirin-Exacerbated Respiratory Disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Biological Therapy; Chronic Disease; Humans; Nasal Polyps; Pilot P | 2022 |
Management of chronic rhinosinusitis with nasal polyps in Samter triad by low-dose ASA desensitization or dupilumab.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Aspirin; Chronic Dis | 2021 |
Omalizumab-Induced Aspirin Tolerance in Nonsteroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease Patients Is Independent of Atopic Sensitization.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Humans; Nasal Polyps; Omalizumab; | 2022 |
Outcomes of aspirin exacerbated respiratory disease patients treated with aspirin desensitization and biologics.
Topics: Aspirin; Asthma, Aspirin-Induced; Biological Products; Chronic Disease; Desensitization, Immunologic | 2022 |
Chronic Rhinosinusitis Outcomes of Patients With Aspirin-Exacerbated Respiratory Disease Treated With Budesonide Irrigations: A Case Series.
Topics: Adrenal Cortex Hormones; Aspirin; Asthma, Aspirin-Induced; Budesonide; Chronic Disease; Humans; Nasa | 2022 |
Comparison of aspirin desensitization outcomes between men and women with AERD.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensitization, Immunologic; Female; Humans; Mal | 2022 |
Dupilumab-associated arthralgia in patients with aspirin-exacerbated respiratory disease.
Topics: Antibodies, Monoclonal, Humanized; Arthralgia; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Hu | 2022 |
Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Eicosanoids; Humans; Nasal Polyps; Prostaglandins | 2022 |
Aspirin desensitization following endoscopic sinus surgery is effective in patients with nonsteroidal antiinflammatory drug exacerbated respiratory disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Chronic Di | 2023 |
The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis.
Topics: Administration, Intranasal; Adrenal Cortex Hormones; Aspirin; Biological Products; Chronic Disease; | 2023 |
Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; Humans; Nasal Poly | 2023 |
Inflammatory mediators in nasal secretions of patients with nasal polyposis with and without aspirin sensitivity.
Topics: Aspirin; Asthma, Aspirin-Induced; Cross-Sectional Studies; Humans; Inflammation Mediators; Nasal Pol | 2023 |
Mechanistic and clinical updates in AERD: 2021-2022.
Topics: Adult; Aspirin; Asthma; Asthma, Aspirin-Induced; Chronic Disease; Humans; Nasal Polyps; Rhinitis | 2023 |
Demographic and clinical profile of patients with chronic rhinosinusitis in Saudi Arabia.
Topics: Aspirin; Asthma; Chronic Disease; Cross-Sectional Studies; Female; Humans; Male; Nasal Polyps; Preva | 2023 |
Co-treatment of non-steroidal anti-inflammatory drug-exacerbated respiratory disease with dupilumab and aspirin therapy after desensitization.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Aspirin; Asthma, Aspirin | 2023 |
Perioperative mepolizumab in aspirin-exacerbated respiratory disease does not prevent nasal polyp regrowth.
Topics: Antibodies, Monoclonal, Humanized; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Humans; Nasal | 2023 |
Association Between Aspirin-Exacerbated Respiratory Disease and Atherosclerotic Cardiovascular Disease: A Retrospective Review of US Claims Data.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Cardiovascular Di | 2023 |
Angiogenesis and eosinophilia in the nasal mucosa of patients with different clinical phenotypes of chronic rhinosinusitis.
Topics: Aspirin; Chronic Disease; Cross-Sectional Studies; Eosinophilia; Humans; Nasal Mucosa; Nasal Polyps; | 2023 |
The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease (AERD) undergoing aspirin desensitization: preliminary data.
Topics: Adult; Aspirin; Asthma, Aspirin-Induced; Bodily Secretions; Chronic Disease; Cytokines; Desensitizat | 2020 |
Symptom Control of Patients With Chronic Rhinosinusitis With Nasal Polyps Under Maintenance Therapy With Daily Acetylsalicylic Acid.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensit | 2020 |
The Burden of Non-steroidal anti-inflammatory exacerbated respiratory disease from the patient's perspective - a qualitative analysis of posts from the Samter's Society.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Cost of Illness; Drug Hypersensit | 2020 |
Surgical outcomes in aspirin-exacerbated respiratory disease without aspirin desensitization.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Endoscopy; Humans; Nasal Polyps; Retrospective St | 2020 |
A Comparison of Sphenoid Sinus Osteoneogenesis in Aspirin-Exacerbated Respiratory Disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Humans; Nasal Polyps; Retrospective Studies; Rhin | 2021 |
Heterogeneity of lower airway inflammation in patients with NSAID-exacerbated respiratory disease.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Biomarkers; Bronchoalveolar L | 2021 |
Aspirin-Exacerbated Respiratory Disease: Association Between Patient-Reported Sinus and Asthma Morbidity.
Topics: Adult; Aspirin; Asthma; Chronic Disease; Female; Humans; Male; Middle Aged; Morbidity; Rhinitis | 2021 |
Level of sex hormones and their association with acetylsalicylic acid intolerance and nasal polyposis.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chronic Disease; Cone-Beam Computed Tomography; Drug Hypers | 2020 |
Dysbiosis in aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Dysbiosi | 2021 |
Perioperative management and perceived risks of sinus surgery in patients with aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Humans; Nasal Polyps; Rhinitis; Sinusitis | 2021 |
Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease.
Topics: Antibodies, Monoclonal, Humanized; Aspirin; Chronic Disease; Cost-Benefit Analysis; Desensitization, | 2021 |
Epithelial dysregulation in chronic rhinosinusitis with nasal polyposis (CRSwNP) and aspirin-exacerbated respiratory disease (AERD).
Topics: Aspirin; Biomarkers; Chronic Disease; Disease Progression; Disease Susceptibility; Humans; Nasal Pol | 2021 |
Long-term Clinical Outcomes of Aspirin Desensitization With Continuous Daily Aspirin Therapy in Aspirin-exacerbated Respiratory Disease.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-In | 2018 |
Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study.
Topics: Administration, Inhalation; Aspirin; Asthma; Case-Control Studies; Chronic Disease; Cross-Sectional | 2018 |
Differences in urinary leukotriene E4 levels and distribution of eosinophils between chronic rhinosinusitis patients with aspirin-intolerant and-tolerant asthma.
Topics: Aspirin; Asthma; Chronic Disease; Drug Tolerance; Eosinophils; Humans; Leukotriene E4; Rhinitis; Sin | 2016 |
A retrospective analysis of esophageal eosinophilia in patients with aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Cyclooxygenase Inhibitors; Desensitization, Immunologic; Eosinophi | 2019 |
A 1-Day, 90-Minute Aspirin Challenge and Desensitization Protocol in Aspirin-Exacerbated Respiratory Disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Cyclooxygenase Inhibitors; Desensitization, Immun | 2019 |
NSAIDs-hypersensitivity often induces a blended reaction pattern involving multiple organs.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Drug Hypersensitivity; Female; Huma | 2018 |
Objective and subjective sinonasal and pulmonary outcomes in aspirin desensitization therapy: A prospective cohort study.
Topics: Aged; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Cohort Studies; Desensitization, Immunologi | 2019 |
[Nasal provocation with increased ASA dose: improved "non-steroidal anti-inflammatory drugs (NSAIDs)-exacerbated disease" (N‑ERD) detection rate in chronic rhinosinusitis patients].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Humans; | 2019 |
The bacteriology of chronic rhinosinusitis and the pre-eminence of Staphylococcus aureus in revision patients.
Topics: Adult; Aged; Aspirin; Asthma; Chronic Disease; Female; Humans; Male; Middle Aged; Nasal Polyps; Pseu | 2013 |
Non-steroidal anti-inflammatory drug hypersensitivity in adults and the factors associated with asthma.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Drug Eruptions; Dr | 2013 |
Aspirin sensitivity does not compromise quality-of-life outcomes in patients with Samter's triad.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; | 2014 |
Nasal lysine aspirin challenge in the diagnosis of aspirin - exacerbated respiratory disease: asthma and rhinitis.
Topics: Adult; Aged; Aspirin; Asthma, Aspirin-Induced; Female; Humans; Lysine; Male; Middle Aged; Nasal Prov | 2013 |
Short-term beneficial effect of aspirin in patient with chronic rhinosinusitis and tolerant to acetylsalicylic acid.
Topics: Adult; Aspirin; Chronic Disease; Humans; Male; Rhinitis; Sinusitis | 2013 |
Systemic prednisone administration selectively alters granulocyte subsets in nasal polyps from aspirin-exacerbated respiratory disease and chronic rhinosinusitis patients.
Topics: Adult; Aged; Aspirin; Chronic Disease; Ethmoid Sinus; Female; Flow Cytometry; Glucocorticoids; Granu | 2013 |
Aspirin desensitization: useful treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in aspirin-exacerbated respiratory disease (AERD)?
Topics: Aspirin; Chronic Disease; Desensitization, Immunologic; Drug Hypersensitivity; Drug Tolerance; Human | 2014 |
Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitizat | 2014 |
Phenotype of asthma related with high serum periostin levels.
Topics: Adult; Asian People; Aspirin; Asthma; Cell Adhesion Molecules; Cytokines; Drug Tolerance; Eosinophil | 2015 |
Outcomes of complete vs targeted approaches to endoscopic sinus surgery.
Topics: Aspirin; Asthma; Chronic Disease; Endoscopy; Female; Humans; Male; Middle Aged; Nasal Polyps; Postop | 2015 |
A conserved linkage group on chromosome 6, the 8.1 ancestral haplotype, is a predisposing factor of chronic rhinosinusitis associated with nasal polyposis in aspirin-sensitive Hungarians.
Topics: Adolescent; Adult; Aged; Alleles; Aspirin; Case-Control Studies; Chromosomes, Human, Pair 6; Chronic | 2015 |
Clinical Examination of Tissue Eosinophilia in Patients with Chronic Rhinosinusitis and Nasal Polyposis.
Topics: Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Eosinophilia; Female; Humans; Male; Middle | 2016 |
Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study.
Topics: Adult; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Cross-Sectional Studies; Female; Humans; L | 2017 |
Oral corticosteroid prescribing habits for rhinosinusitis: The American Rhinologic Society membership.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aspirin; Chronic Disease; Evidence-Based Medicine; Hu | 2017 |
Correlation between the prostaglandin D(2)/E(2) ratio in nasal polyps and the recalcitrant pathophysiology of chronic rhinosinusitis associated with bronchial asthma.
Topics: Adult; Aged; Aspirin; Asthma; Cell Extracts; Chronic Disease; Dinoprostone; Drug Hypersensitivity; E | 2008 |
Otologic manifestations in Samter's syndrome.
Topics: Aspirin; Asthma; Chronic Disease; Cohort Studies; Drug Hypersensitivity; Ear Diseases; Ear, Middle; | 2009 |
Proteomics blood testing to distinguish chronic rhinosinusitis subtypes.
Topics: Aspirin; Asthma; Biomarkers; Chronic Disease; Diagnosis, Differential; Drug Hypersensitivity; Fungi; | 2008 |
Immediate rhinoconjunctivitis induced by metamizole: an allergic reaction?
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Conjunctivitis, Allergic; Di | 2010 |
[The treatment of polypous suppurative rhinosinusitis in the patients presenting with the severe and moderate aspirin triad].
Topics: Aspirin; Asthma; Humans; Nasal Polyps; Rhinitis; Sinusitis; Suppuration | 2011 |
Improvement of chronic rhinitis under aspirin.
Topics: Aspirin; Chronic Disease; Cyclooxygenase Inhibitors; Humans; Magnetic Resonance Imaging; Male; Middl | 2012 |
Low SPINK5 expression in chronic rhinosinusitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; | 2012 |
Incidence of aspirin hypersensitivity in patients with chronic rhinosinusitis and diagnostic value of urinary leukotriene E4.
Topics: Adult; Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Female; Humans; Leukotriene E4; Male | 2012 |
A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Case-Control Studies; Drug Hypersensitivit | 2002 |
The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Provoca | 2002 |
The natural history and clinical characteristics of aspirin-exacerbated respiratory disease.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Provocatio | 2002 |
[THERAPEUTIC USE OF THE COMBINATION OF CHYMOTRYPSIN WITH ACETYLSALICYLIC ACID IN PEDIATRICS].
Topics: Analgesics; Analgesics, Non-Narcotic; Antipyretics; Aspirin; Bronchitis; Child; Chymotrypsin; Fever; | 1963 |
COMPARATIVE EFFECTIVENESS OF THREE ORAL MEDICATIONS IN SINUSTIS AND RHINITIS; A DOUBLE-BLIND STUDY.
Topics: Anti-Allergic Agents; Aspirin; Biomedical Research; Codeine; Double-Blind Method; Headache; Histamin | 1964 |
[VALUE OF CHYMALGYL IN OTORHINOLARYNGOLOGICAL PATHOLOGY. APROPOS OF 20 CASES].
Topics: Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antipyretics; Aspirin; Drug Therapy; | 1965 |
Aspirin-sensitive rhinitis-associated changes in upper airway innervation.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Male; Mid | 2003 |
Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Case-Contr | 2004 |
Dynamics of COX-2 in nasal mucosa and nasal polyps from aspirin-tolerant and aspirin-intolerant patients with asthma.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cyclooxygenase 1; Cyclooxygenase 2; | 2004 |
Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis.
Topics: Adult; Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Enterotoxins; Female; Humans; Immuno | 2004 |
Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Epithelial Cells; Fe | 2005 |
Improvements in an oral aspirin challenge protocol for the diagnosis of aspirin hypersensitivity.
Topics: Administration, Oral; Adult; Anaphylaxis; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspir | 2005 |
Aspirin-triggered 15-HETE generation in peripheral blood leukocytes is a specific and sensitive Aspirin-Sensitive Patients Identification Test (ASPITest).
Topics: Adult; Aged; Aspirin; Asthma; Drug Hypersensitivity; Female; Humans; Hydroxyeicosatetraenoic Acids; | 2005 |
[New pathophysiological concepts on aspirin hypersensitivity (Widal syndrome); diagnostic and therapeutic consequences].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; Drug Hypersensitiv | 2005 |
Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy; Chronic Disease; Drug Hyperse | 2006 |
Aspirin induced asthma (AIA) with nasal polyps has the highest basal LTE4 excretion: a study vs AIA without polyps, mild topic asthma, and normal controls.
Topics: Adult; Aspirin; Asthma; Biomarkers; Bronchial Provocation Tests; Humans; Leukotriene E4; Middle Aged | 2006 |
Does it make sense to "desens"? Aspirin desensitization in the treatment of chronic rhinosinusitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; Desensitization, Immunolo | 2006 |
Expression of cyclooxygenase and lipoxygenase enzymes in nasal polyps of aspirin-sensitive and aspirin-tolerant patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cyclooxygenase 1; Cyclooxyge | 2006 |
Association between a TGFbeta1 promoter polymorphism and rhinosinusitis in aspirin-intolerant asthmatic patients.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Drug Hypersensitivity; Female; Gene | 2007 |
Allergy and sinus disease.
Topics: Anti-Allergic Agents; Aspirin; Drug Hypersensitivity; Humans; Nasal Polyps; Respiratory Hypersensiti | 2006 |
Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Desensitization, Immunologic; Drug Hyperse | 2007 |
Impact of aspirin intolerance on outcomes of sinus surgery.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chi-Square Distribution; Chronic Dise | 2007 |
The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Asthma; Child; Child, Preschool; Chronic Diseas | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
BSACI guidelines for the management of rhinosinusitis and nasal polyposis.
Topics: Aspirin; Child; Churg-Strauss Syndrome; Female; Humans; Male; Nasal Polyps; Rhinitis; Sinusitis | 2008 |
Aspirin-sensitive asthma and rhinosinusitis: current concepts and recent advances.
Topics: Adult; Aspirin; Asthma; Desensitization, Immunologic; Drug Tolerance; Humans; Rhinitis; Sinusitis | 1984 |
[Bronchial asthma, nasal polyposis and analgesic intolerance (the ASA triad). A successful computer based analysis of free texts].
Topics: Analgesics; Aspirin; Asthma; Chronic Disease; Computers; Drug Tolerance; Humans; Nasal Polyps; Rhini | 1984 |
[Rhinosinusitis polyposa and intolerance to analgesics (aspirin intolerance)].
Topics: Adult; Aged; Analgesics; Aspirin; Bronchial Provocation Tests; Drug Hypersensitivity; Drug Tolerance | 1983 |
Aspirin intolerance presenting as chronic rhinitis.
Topics: Aspirin; Chronic Disease; Diagnosis, Differential; Drug Hypersensitivity; Eosinophilia; Female; Head | 1980 |
Aspirin-induced asthma in children.
Topics: Acetylation; Adolescent; Anti-Inflammatory Agents; Aspirin; Asthma; Child; Complement System Protein | 1982 |
Evaluation of intolerance to analgesics, preservatives and food colorants with challenge tests.
Topics: Adolescent; Adult; Aged; Aspirin; Asthma; Bronchial Provocation Tests; Child; False Negative Reactio | 1982 |
[Broncaspin in the therapy of pediatric diseases of the respiratory tract].
Topics: Age Factors; Anti-Bacterial Agents; Aspirin; Bronchitis; Bronchopneumonia; Child; Child, Preschool; | 1981 |
Nasal secretions in response to acetylsalicylic acid.
Topics: Adult; Aged; Aspirin; Asthma; Drug Hypersensitivity; Female; Humans; Inflammation; Male; Middle Aged | 1993 |
Medical management of sinusitis.
Topics: Adrenal Cortex Hormones; Aspirin; Drainage; Humans; Hypersensitivity; Nasal Decongestants; Nasal Sep | 1998 |
[A case of aspirin triad].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Drug Hypersensitivity; Follow-Up | 1999 |
NSAID-induced bronchospasm--a common and serious problem. A report from MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority.
Topics: Adult; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Spasm; Chroni | 1999 |
Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry.
Topics: Administration, Intranasal; Adult; Aged; Aspirin; Asthma; Cyclooxygenase Inhibitors; Female; Humans; | 2000 |
[Family study of patients with aspirin intolerance and rhinosinusitis].
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Provocation T | 2000 |
Individual monitoring of aspirin desensitization.
Topics: Adult; Aged; Aspirin; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Male; Mid | 2001 |
Aspirin desensitization for chronic hyperplastic sinusitis, nasal polyposis, and asthma triad.
Topics: Adult; Aged; Aspirin; Asthma; Chronic Disease; Desensitization, Immunologic; Drug Hypersensitivity; | 2001 |
Decreased apoptosis and distinct profile of infiltrating cells in the nasal polyps of patients with aspirin hypersensitivity.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; Antigens, Differentiation, Myelo | 2002 |
Rhinitis medicamentosa.
Topics: Antihypertensive Agents; Aspirin; Cocaine; Drug-Related Side Effects and Adverse Reactions; Estrogen | 1979 |
Aspirin idiosyncrasy.
Topics: Aspirin; Asthma; Drug Hypersensitivity; Humans; Male; Middle Aged; Nasal Polyps; Rhinitis | 1979 |
Hypersensitivity to nonsteroidal antiinflammatory drugs: indications and methods for oral challenges.
Topics: Anti-Inflammatory Agents; Aspirin; Asthma; Bronchial Provocation Tests; Drug Hypersensitivity; Human | 1979 |
Aspirin intolerance in asthmatic patients: case histories.
Topics: Adult; Aspirin; Asthma; Female; Humans; Rhinitis; Sinusitis | 1977 |
Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients.
Topics: Adult; Aged; Analgesics; Aspirin; Asthma; Bronchi; Drug Hypersensitivity; Female; Flufenamic Acid; H | 1975 |
Intolerance to aspirin.
Topics: Aspirin; Asthma; Drug Hypersensitivity; Humans; Nasal Polyps; Rhinitis | 1975 |
Tryptase and histamine release during aspirin-induced respiratory reactions.
Topics: Administration, Oral; Adult; Aspirin; Asthma; Forced Expiratory Volume; Histamine; Histamine Release | 1991 |
Inhalation and nasal challenge in the diagnosis of aspirin-induced asthma.
Topics: Adult; Aged; Aspirin; Asthma; Bronchial Provocation Tests; Female; Forced Expiratory Volume; Humans; | 1991 |
Long-term effects of aspirin desensitization--treatment for aspirin-sensitive rhinosinusitis-asthma.
Topics: Adrenal Cortex Hormones; Adult; Aspirin; Asthma; Combined Modality Therapy; Desensitization, Immunol | 1990 |
Nonallergic rhinitis with eosinophilia syndrome a precursor of the triad: nasal polyposis, intrinsic asthma, and intolerance to aspirin.
Topics: Adolescent; Adult; Aspirin; Asthma; Child; Drug Tolerance; Eosinophilia; Female; Humans; Male; Middl | 1990 |
[NARES syndrome. A developing link in the Fernand-Widal triad].
Topics: Adult; Aspirin; Asthma; Autonomic Nervous System Diseases; Eosinophilia; Female; Humans; Male; Middl | 1989 |
[Clinical aspect of aspirin-induced asthma].
Topics: Adult; Aspirin; Asthma; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Nasal Polyps; Para | 1985 |
[Diagnostic and therapeutic methods in the asthmatic triad].
Topics: Adolescent; Adult; Aspirin; Asthma; Bronchial Provocation Tests; Child; Desensitization, Immunologic | 1985 |
Rhinitis medicamentosa.
Topics: Aspirin; Cocaine; Drug Hypersensitivity; Ephedrine; Epinephrine; Estrogens; Humans; Iodides; Ipecac; | 1968 |
Familial occurrence of asthma, nasal polyps and aspirin intolerance.
Topics: Adult; Aspirin; Asthma; Diseases in Twins; Drug Hypersensitivity; Environment; Female; Genotype; Hum | 1973 |
[Aspirin intolerance in a child].
Topics: Adolescent; Aspirin; Asthma; Bronchodilator Agents; Child; Drug Hypersensitivity; Fever; Humans; Mal | 1973 |
Urticaria induced by preservatives and dye additives in food and drugs.
Topics: Angioedema; Aspirin; Azo Compounds; Benzoates; Coloring Agents; Drug Hypersensitivity; Erythema; Foo | 1973 |
Aspirin and other cross-reacting small chemicals in known aspirin intolerant patients.
Topics: Analgesics; Antioxidants; Aspirin; Asthma; Blood Coagulation; Cross Reactions; Dose-Response Relatio | 1973 |
Tween 80 exacerbated intrinsic rhinitis and asthma in non-aspirin-sensitive patients.
Topics: Aspirin; Asthma; Blood Vessels; Chemical Phenomena; Chemistry; Cholestyramine Resin; Diabetes Compli | 1974 |
Concerning the nature of intolerance to aspirin.
Topics: Aminopyrine; Antipyrine; Aspirin; Asthma; Chemoreceptor Cells; Drug Hypersensitivity; Edema; Histami | 1967 |
Acetylation of human serum albumin by acetylsalicylic acid.
Topics: Acetates; Acetrizoic Acid; Alkylation; Animals; Aspirin; Asthma; Autoradiography; Carbon Isotopes; C | 1968 |